# EDGAR Filing Document

**Accession Number:** 0001684688
**File Stem:** 0001493152-26-001869
**Filing Date:** 2026-1
**Character Count:** 297008
**Document Hash:** 6b25c4b224c1c533e9d50a4485621fde
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-001869.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001493152-26-001869

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 7

**CONFORMED PERIOD OF REPORT**: 20260112

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ATLAS CRITICAL MINERALS Corp
- **CENTRAL INDEX KEY:** 0001684688
- **STANDARD INDUSTRIAL CLASSIFICATION:** GOLD & SILVER ORES [1040]
- **ORGANIZATION NAME:** 01 Energy & Transportation
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 1T
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43042
- **FILM NUMBER:** 26527353

**BUSINESS ADDRESS:**
- **STREET 1:** BELO HORIZONTE
- **CITY:** MINAS GERAIS
- **STATE:** D5
- **ZIP:** 30112-010
- **BUSINESS PHONE:** 55-31-3956-1109

**MAIL ADDRESS:**
- **STREET 1:** BELO HORIZONTE
- **CITY:** MINAS GERAIS
- **STATE:** D5
- **ZIP:** 30112-010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Jupiter Gold Corp
- **DATE OF NAME CHANGE:** 20160914

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

**Commission File Number 001-43042**

**<u>ATLAS CRITICAL MINERALS CORPORATION</u>**

(Translation of registrant's name into English)

**Rua Antônio de Albuquerque, 156, Suite 1720**

**<u>Belo Horizonte, Minas Gerais, Brazil, 30112-010</u>**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Pricing and Closing of $11.0 Million Public Offering**

On January 8, 2026, Atlas Critical Minerals Corporation (the "Company"), entered into an underwriting agreement (the "Underwriting Agreement") with A.G.P./Alliance Global Partners ("A.G.P.") and Banco Bradesco BBI S.A., as representatives of the underwriters, pursuant to which the Company agreed to sell to the underwriters in a firm commitment underwritten public offering (the "Offering") an aggregate of 1,200,000 shares of common stock of the Company, par value $0.001 per share (the "Common Stock"), at a public offering price of $8.00 per share. The Company granted the underwriters a 45-day option to purchase up to an additional 180,000 shares of Common Stock to cover over-allotments (the "Over-Allotment Option"). On January 11, 2026, the underwriters exercised the Over-Allotment Option in full, generating additional gross proceeds to the Company of approximately $1.4 million. As a result of the full exercise of the Over-Allotment Option, total gross proceeds to the Company from the Offering were approximately $11.0 million, and net proceeds were approximately $9.7 million. The Offering, including the shares issuable upon the exercise of the Over-Allotment Option, closed on January 12, 2026.

The shares of Common Stock were offered by the Company pursuant to a registration statement on Form F-1, as amended (File No. 333-290242), filed with the Securities and Exchange Commission (the "Commission"), which became effective in accordance with the provisions of Section 8(a) of the Securities Act of 1933, as amended (the "Securities Act"), on January 8, 2026, and an additional registration statement on Form F-1 MEF (File No. 333-292623) filed with the Commission pursuant to Rule 462(b) promulgated under the Securities Act on January 8, 2026, which became automatically effective upon filing. The Common Stock was also approved for listing on the Nasdaq Capital Market on January 8, 2026, and commenced trading on the Nasdaq under the ticker symbol "ATCX" on January 9, 2026.

The Company anticipates using the net proceeds from the Offering to advance exploration and development activities across its critical minerals project portfolio in Brazil, with any surplus intended to be used for general working capital, cash reserves, or other corporate purposes at the discretion of management.

The Underwriting Agreement contains customary representations and warranties that the parties made to, and solely for the benefit of, the other party in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between the parties. The provisions of the Underwriting Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to such agreements and are not intended as documents for investors and the public to obtain factual information about the current state of affairs of the parties to those documents and agreements.

Investors and the public should look to other disclosures contained in the Company's filings with the Commission for information on the Company's business and financial matters.

Pursuant to the terms of the Underwriting Agreement, the Company granted A.G.P. warrants (the "Representative's Warrants") to purchase up to 82,800 shares of the Company's Common Stock, representing six percent (6.0%) of the total number of shares of Common Stock sold in the Offering at an exercise price equal to $9.20, which is 115% of the underwritten offering price in the Offering. The Representative's Warrants will be non-exercisable for 180 days after the date of the commencement of sales in the Offering and will expire five (5) years after such date of the commencement of sales in the Offering, in accordance with Financial Industry Regulatory Authority Rule 5110(e)(1).

On January 12, 2026, the Company entered into a Financial Advisory Agreement with A.G.P. pursuant to which the Company agreed to pay A.G.P. a financial advisory fee of $135,000 for the provision of certain financial services related to the Offering.

The foregoing summary of the terms of the Underwriting Agreement, the Financial Advisory Agreement and the Representative's Warrants is subject to, and qualified in its entirety by reference to, a copy of the Underwriting Agreement, a copy of the Financial Advisory Agreement and a copy of the form of the Representative's Warrant filed as Exhibits 1.1, 1.2 and 4.1, respectively, to this Report on Form 6-K and incorporated herein by reference.

A copy of the press release issued by the Company announcing the closing of the Offering is filed as Exhibit 99.1 hereto and incorporated by reference herein.

**Exhibits**

The following exhibits are included in this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 1.1 | [Underwriting Agreement](ex1-1.htm) |
| 1.2 | [Financial Advisory Agreement](ex1-2.htm) |
| 4.1 | [Form of Representative's Warrant](ex4-1.htm) |
| 99.1 | [Press release announcing closing of the Offering](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 12, 2026 | **Atlas Critical Minerals Corporation** | **Atlas Critical Minerals Corporation** |
|  | By: | */s/ Marc Fogassa* |
|  |  | Marc Fogassa |
|  |  | Chief Executive Officer |

---

## Exhibit 1.1

**Exhibit 1.1**

**<u>EXECUTION VERSION</u>**

**Atlas Critical Minerals Corporation**

**<u>UNDERWRITING AGREEMENT</u>**

January 8, 2026

A.G.P./Alliance Global Partners

Banco Bradesco BBI S.A.

As Representatives of the several Underwriters named on <u>Schedule 1</u> attached hereto

c/o A.G.P./Alliance Global Partners

590 Madison Avenue, 28th Floor

New York, New York 10022

Banco Bradesco BBI S.A.

Avenida Juscelino Kubitschek, 1,309, 10<sup>th</sup> Floor<br> 04543-011 São Paulo, São Paulo, Brazil

Ladies and Gentlemen:

The undersigned, Atlas Critical Minerals Corporation, a Republic of the Marshall Islands corporation (the "**Company**"), hereby confirms its agreement (this "**Agreement**") with A.G.P./Alliance Global Partners ("**A.G.P.**") and Banco Bradesco BBI S.A. (hereinafter referred to as "you" (including its correlatives) or the "**Representatives**" or, individually, the "**Representative**") and with the other underwriters named on <u>Schedule 1</u> hereto (if any) for which the Representatives are acting as representatives (the Representatives and such other underwriters being collectively called the "**Underwriters**" or, individually, an "**Underwriter**") as follows:

---

| | |
|:---|:---|
| **1** | **<u>Purchase and Sale of Securities</u>** |

---

1.1  **<u>Firm Shares</u>** 

1.1.1  **<u>Nature and Purchase of Shares</u>** 

1.1.1.1 On
 the basis of the representations and warranties herein contained, but subject to the terms
 and conditions herein set forth, the Company agrees to issue and sell to the several Underwriters,
 an aggregate of 1,200,000 shares (the "**Firm Shares**") of the Company's
 common stock, par value $0.001 per share (the "**Common Stock** ").

1.1.1.2 The
 Underwriters, severally and not jointly, agree to purchase from the Company the number of
 Firm Shares set forth opposite their respective names on <u>Schedule 1</u> attached hereto
 and made a part hereof. The purchase price for one Firm Share shall be $7.44 (net of
 underwriting discounts) (the "**Purchase Price** "). The Firm Shares are to
 be offered initially to the public at the offering price set forth on the cover page of the
 Prospectus (as defined in Section 2.1.1 hereof); provided, however, the parties agree and
 acknowledge that the Purchase Price shall be $7.76 (net of underwriting discounts) for
 each Firm Share sold to accounts introduced to the Underwriters by the Company as listed
 in <u>Exhibit C</u> attached hereto ()"**Company Introduced Accounts** "), provided,
 further that such Firm Shares shall be offered and sold to Company Introduced Accounts at
 the price set forth on the cover page of the Prospectus.

1.1.1.3  **<u>Firm Shares Payment and Delivery</u>** 

1.1.1.3 Delivery
 and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the first (1st)
 Business Day following the effective date (the "**Effective Date**") of the
 Registration Statement (as defined in Section 2.1.1 below) under the Securities Act of 1933,
 as amended (the "**Securities Act**") (or the second (2nd) Business Day following
 the Effective Date if the pricing for the Offering (as defined in Section 1.2.1 below) occurs
 after 4:01 p.m., Eastern time on the Effective Date) or at such earlier time as shall be
 agreed upon by the Representatives and the Company, at the offices of Blank Rome LLP, 1271
 Avenue of the Americas, New York, New York 10020 ()"**Representatives Counsel** "),
 or at such other place (or remotely by facsimile or other electronic transmission) as shall
 be agreed upon by the Representatives and the Company. The hour and date of delivery and
 payment for the Firm Shares is called the "**Closing Date**."

1.1.1.4 Payment
 for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day)
 funds, payable to the order of the Company upon delivery of the Firm Shares via the Depository
 Trust Company ()"**DTC** "). The Firm Shares shall be registered in such name
 or names and in such authorized denominations as the Representatives may request in
 writing at least two (2) full Business Days prior to the Closing Date. The Company shall
 not be obligated to sell or deliver the Firm Shares except upon tender of payment by the
 Representatives for all of the Firm Shares. The term "**Business Day** "
 means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking
 institutions are authorized or obligated by law to close in New York, New York.

1.2  **<u>Over-allotment Option</u>** 

1.2.1  **<u>Option Shares</u>** . For the purposes of covering any over-allotments in connection with the distribution
 and sale of the Firm Shares, the Company hereby grants to the Underwriters an option (the
 "**Over-Allotment Option**") to purchase at the Purchase Price up to an additional
 180,000 shares of Common Stock from the Company, representing fifteen percent (15%) of the
 Firm Shares sold in the offering (the "**Option Shares** "). The Firm Shares
 and the Option Shares are hereinafter referred to together as the "**Shares**."
 The offering and sale of the Shares is hereinafter referred to as the "**Offering**."

1.2.2  **<u>Exercise of Over-Allotment Option</u>** . The Over-Allotment Option granted pursuant to Section 1.2.1
 hereof may be exercised by the Underwriters as to all (at any time) or any part (from time
 to time) of the Option Shares within forty-five (45) days after the date of the Prospectus
 (as defined below). The Underwriters shall not be under any obligation to purchase any Option
 Shares prior to the exercise of the Over-Allotment Option. The Over-Allotment Option granted
 hereby may be exercised by the giving of oral notice to the Company from the Representatives,
 which must be confirmed in writing by overnight mail or facsimile or other electronic transmission
 setting forth the number of Option Shares to be purchased and the date and time for delivery
 of and payment for the Option Shares (the "**Option Closing Date** "), which
 shall not be later than five (5) full Business Days after the date of first notice or such
 other time as shall be agreed upon by the Company and the Representative, at the
 offices of Representatives Counsel, or at such other place (including remotely by
 facsimile or other electronic transmission) as shall be agreed upon by the Company and the
 Representative. Upon exercise of the Over-Allotment Option with respect to all or any portion
 of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company
 shall become obligated to sell to the Underwriters the number of Option Shares specified
 in such notice and (ii) each of the Underwriters, acting severally and not jointly, shall
 purchase that portion of the total number of Option Shares then being purchased as set forth
 in Schedule 1 opposite the name of such Underwriter.

1.2.3  **<u>Payment and Delivery</u>** . Payment for the Option Shares shall be made on the Option Closing Date
 by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery
 to you of certificates (in form and substance satisfactory to the Underwriters) representing
 the Option Shares (or through the facilities of DTC) for the account of the Underwriters.
 The Option Shares shall be registered in such name or names and in such authorized denominations
 as the Representatives may request in writing at least two (2) full Business Days
 prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the
 Option Shares except upon tender of payment by the Underwriters for applicable Option Shares.

1.3  **<u>Representative's Warrants</u>** 

1.3.1  **<u>Warrant Issuance</u>** . The Company hereby agrees to issue to A.G.P. (and/or its designees)
 on the Closing Date, and each Option Closing Date, a warrant (each a "**Representative's Warrant**" and collectively, the "**Representative's Warrants** ")
 to purchase such number of shares of Common Stock equal to six percent (6.0%) of the number
 of Shares purchased on such Closing Date or Option Closing Date, as the case may be (the
 "**Representative's Warrant Shares** "). The Representative's Warrant
 Agreement, in the form attached hereto as <u>Exhibit A</u> (the "**Representative's Warrant Agreement** "), provides that in compliance with FINRA Rule 5110(e), the Representative's
 Warrants shall be exercisable, in whole or in part, commencing 180 days after the Commencement
 Date, which is described in the Representative's Warrant Agreement as the Effective
 Date and expiring on the five year anniversary of the Effective Date at an initial exercise
 price per Common Share of $9.20, which is equal to 115% of the Purchase Price.

1.3.2  **<u>Delivery</u>** .
 Delivery of the Representative's Warrant Agreement shall be made on the Closing Date
 and shall be issued in the name or names and in such authorized denominations as the Representatives
 may reasonably request.

---

| | |
|:---|:---|
| 2 | **<u>Representations and Warranties of the Company</u>** |

---

The Company represents and warrants to the Underwriters as of the Applicable Time (as defined below), as of the Closing Date and as of the Option Closing Date, as follows:

2.1  **<u>Filing of Registration Statement</u>** 

2.1.1  **<u>Pursuant to the Securities Act</u>** . The Company has filed with the U.S. Securities and Exchange Commission (the
 "**Commission**") an initial registration statement, and an amendment or amendments thereto, on Form F-1 (File No.
 333-290242), including any related prospectus or prospectuses, for the registration of the sale of Shares under the Securities Act,
 which registration statement and amendment or amendments have been prepared by the Company in all material respects in conformity
 with the requirements of the Securities Act and the rules and regulations of the Commission promulgated thereunder (the
 "**Securities Act Regulations**") and contains and will contain all material statements that are required to be
 stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the context may otherwise
 require, such registration statement, as amended, on file with the Commission at the time the registration statement became
 effective (including the Preliminary Prospectus included in the registration statement, financial statements, schedules, exhibits
 and all other documents filed as a part thereof and all information deemed to be a part thereof as of the Effective Date pursuant to
 paragraph (b) of Rule 430A of the Securities Act Regulations (the "**Rule 430A Information** ")), is referred to
 herein as the "**Registration Statement**." The Company filed a registration statement pursuant to Rule 462(b) (the
 "Rule 462(b) Registration Statement") of the Securities Act Regulations, which became effective upon filing on January 8, 2026, therefore, the term
 "Registration Statement" includes the Rule 462(b) Registration Statement filed pursuant to Rule 462(b). The Registration
 Statement has been declared effective by the Commission on the date hereof. Each prospectus used prior to the effectiveness of the
 Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior
 to the execution and delivery of this Agreement, is herein called a "**Preliminary Prospectus**." The Preliminary
 Prospectus, subject to completion, dated January 2, 2026, which was included in the Registration Statement immediately prior to the
 Applicable Time (as defined herein) is hereinafter called the "**Pricing Prospectus**." The final prospectus in the
 form first furnished to the Underwriters for use in the Offering is hereinafter called the "**Prospectus**." Any
 reference to the "**most recent Preliminary Prospectus**" shall be deemed to refer to the latest Preliminary
 Prospectus included in the Registration Statement.

"**Applicable Time**" means 5:30 p.m., Eastern Time, on the date of this Agreement.

"**Issuer Free Writing Prospectus**" means any "issuer free writing prospectus," as defined in Rule 433 of the Securities Act Regulations ("**Rule 433**"), including without limitation any "free writing prospectus" (as defined in Rule 405 of the Securities Act Regulations) relating to the Shares that is (i) required to be filed with the Commission by the Company, (ii) a "road show that is a written communication" within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Shares or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company's records pursuant to Rule 433(g).

"**Issuer General Use Free Writing Prospectus**" means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a "*bona fide* electronic road show," as defined in Rule 433), as evidenced by its being specified in Schedule 2-B hereto.

"**Issuer Limited Use Free Writing Prospectus**" means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.

"**Pricing Disclosure Package**" means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Pricing Prospectus and the information included on <u>Schedule 2-A</u> hereto, all considered together.

2.1.2  **<u>Pursuant to the Exchange Act</u>** . The Company has filed with the Commission a Form 8-A (File Number
 001-43042) (the "**Form 8-A Registration Statement**") providing for the
 registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended
 (the "**Exchange Act** "), of the Common Stock. The registration of the Common
 Stock and the related Form 8-A filed under the Exchange Act has been declared effective by
 the Commission on or prior to the date hereof. The Company has taken no action designed to,
 or likely to have the effect of, terminating the registration of the Common Stock under the
 Exchange Act, nor has the Company received any notification that the Commission is contemplating
 terminating such registration.

2.2  **<u>No Stop Orders, etc.</u>** Neither the Commission nor, to the Company's knowledge, any
 state regulatory authority has issued any order preventing or suspending the use of the Registration
 Statement, any Preliminary Prospectus or the Prospectus or has instituted or, to the Company's
 knowledge, threatened to institute, any proceedings with respect to such an order. The Company
 has complied with each request (if any) from the Commission for additional information.

2.3  **<u>Exchange Listing</u>** . The Common Stock has been approved for listing on the Nasdaq Capital Market
 (the "**Exchange** "), subject only to the official notice of issuance and
 evidence of satisfactory distribution. The Company is in compliance with all applicable listing
 requirements of the Exchange, subject to the completion of the Offering.

2.4  **<u>Disclosures in Registration Statement</u>** 

2.4.1  **<u>Compliance with Securities Act and 10b-5 Representation</u>** 

2.4.1.1 Each
 of the Registration Statement and any post-effective amendment thereto, at the time it became
 effective, complied in all material respects with the requirements of the Securities Act
 and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
 filed as part of the Registration Statement as originally filed or as part of any amendment
 or supplement thereto, and the Prospectus, at the time each was filed with the Commission,
 complied in all material respects with the requirements of the Securities Act and the Securities
 Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection
 with this Offering and the Prospectus was or will be identical to the electronically transmitted
 copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
 by Regulation S-T.

2.4.1.2 Neither
 the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable
 Time, at the Closing Date or at any Option Closing Date (if any), contained, contains or
 will contain an untrue statement of a material fact or omitted, omits or will omit to state
 a material fact required to be stated therein or necessary to make the statements therein
 not misleading; provided, however, that this representation and warranty shall not apply
 to statements made or statements omitted in reliance upon and in conformity with written
 information furnished to the Company with respect to the Underwriters by the Underwriters
 expressly for use in the Registration Statement, the Pricing Prospectus or the Prospectus
 or any amendment thereof or supplement thereto. The parties acknowledge and agree such information
 consists solely of the following disclosure in the "Underwriting" section of
 the Prospectus: the table showing the number of shares to be purchased by each Underwriter,
 the third paragraph, the fourth paragraph under the heading "—Discounts, Commissions,
 and Representative's Warrants", the second paragraph under the heading "—Electronic
 Distribution"; the disclosure under the heading "—Price Stabilization,
 Short Positions, and Penalty Bids" and the disclosure under the heading "Offer
 Restrictions Outside the United States" (collectively, the "**Underwriters' Information** ").

2.4.1.3 The
 Pricing Disclosure Package, as of the Applicable Time, at the Closing Date, or at any Option
 Closing Date (if any), did not, does not and will not include an untrue statement of a material
 fact or omit to state a material fact necessary in order to make the statements therein,
 in the light of the circumstances under which they were made, not misleading; and each Issuer
 Limited Use Free Writing Prospectus hereto does not conflict in any material respects with
 the information contained in the Registration Statement, any Preliminary Prospectus, the
 Pricing Prospectus or the Prospectus, and each such Issuer Limited Use Free Writing Prospectus,
 as supplemented by and taken together with the Prospectus as of the Applicable Time, did
 not include an untrue statement of a material fact or omit to state a material fact necessary
 in order to make the statements therein, in the light of the circumstances under which they
 were made, not misleading; provided however, that this representation and warranty shall
 not apply to statements made or statements omitted in reliance upon and in conformity with
 written information furnished to the Company with respect to the Underwriters by the Representatives
 expressly for use in the Registration Statement, the Pricing Prospectus, the Pricing Disclosure
 Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge
 and agree that such information provided by or on behalf of any Underwriter consists solely
 of the Underwriters' Information.

2.4.1.4 Neither
 the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper),
 as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b),
 at the Closing Date, or at any Option Closing Date (if any), included, includes or will include
 an untrue statement of a material fact or omitted, omits or will omit to state a material
 fact necessary in order to make the statements therein, in the light of the circumstances
 under which they were made, not misleading; provided, however, that this representation and
 warranty shall not apply to the Underwriters' Information.

2.4.2  **<u>Disclosure of Agreements</u>** . The agreements and documents described in the Registration Statement,
 the Pricing Disclosure Package and the Prospectus conform in all material respects to the
 descriptions thereof contained therein, and there are no agreements or other documents required
 by the Securities Act and the Securities Act Regulations to be described in the Registration
 Statement, the Pricing Disclosure Package and the Prospectus or to be filed with the Commission
 as exhibits to the Registration Statement, that have not been so described or filed. Each
 agreement or other instrument (however characterized or described) to which the Company is
 a party or by which it is or may be bound or affected and (i) that is referred to in the
 Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii) is material
 to the Company's business, has been duly authorized and validly executed by the Company,
 is in full force and effect in all material respects and is enforceable against the Company
 and, to the Company's knowledge, the other parties thereto, in accordance with its
 terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization
 or similar laws affecting creditors' rights generally, (y) as enforceability of any
 indemnification or contribution provision may be limited under the federal and state securities
 laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable
 relief may be subject to the equitable defenses and to the discretion of the court before
 which any proceeding therefor may be brought. None of such agreements or instruments has
 been assigned by the Company, and neither the Company nor, to the Company's knowledge,
 any other party is in default thereunder and, to the Company's knowledge, no event
 has occurred that, with the lapse of time or the giving of notice, or both, would constitute
 a default thereunder except for a default or event which would not reasonably be expected
 to result in a Material Adverse Effect (as such term is defined in Section 2.4.3 below).
 To the Company's knowledge, performance by the Company of the material provisions of
 such agreements or instruments will not result in a violation of any existing applicable
 law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic
 or foreign, having jurisdiction over the Company or any of its assets or businesses (each,
 a "**Governmental Entity** "), including, without limitation, those relating
 to environmental laws and regulations.

2.4.3  **<u>Organization and Qualification</u>** . The Company is an entity duly incorporated or otherwise organized,
 validly existing, and, if applicable under the laws of the jurisdiction in which they are
 formed, in good standing under the laws of the jurisdiction of its incorporation or organization,
 with the requisite power and authority to own and use its properties and assets and to carry
 on its business as currently conducted. The Company has all necessary authorizations, approvals,
 orders, licenses, certificates and permits of and from all governmental regulatory officials
 and bodies that it needs as of the date hereof to conduct its business purpose in all material
 respects as described in the Registration Statement and to own or lease its properties. The
 Company is not in violation nor default of any of the provisions of its certificate or articles
 of incorporation, bylaws or other organizational or charter documents"). The Company
 is duly qualified to conduct business and is in good standing as a foreign corporation or
 other entity in each jurisdiction in which the nature of the business conducted or property
 owned by it makes such qualification necessary, except where the failure to be so qualified
 or in good standing, as the case may be, could not have or reasonably be expected to result
 in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement,
 (ii) a material adverse effect on the results of operations, assets, business, or condition
 (financial or otherwise) of the Company, taken as a whole, or (iii) a material adverse effect
 on the Company's ability to perform in any material respect on a timely basis its obligations
 under this Agreement (any of (i), (ii) or (iii), a "**Material Adverse Effect** ")
 and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
 or seeking to revoke, limit or curtail such power and authority or qualification. The Company
 has no subsidiaries, aside from the following: Mineração Jupiter Ltda, Mineração
 Apollo Ltda, Mineração Duas Barras Ltda, and RST Recursos Minerais Ltda.

2.4.4  **<u>Authorization; Enforcement</u>** . The Company has the requisite corporate power and authority to enter
 into and to consummate the transactions contemplated by this Agreement and the Representative's
 Warrant Agreement and otherwise to carry out its obligations hereunder and thereunder. The
 execution and delivery of this Agreement and the Representative's Warrant Agreement,
 and the consummation by each of the transactions contemplated hereby and thereby have been
 duly authorized by all necessary action on the part of the Company and no further action
 is required by the Company, the Board of Directors or the Company's shareholders in
 connection herewith or therewith other than in connection with the Required Approvals. This
 Agreement and the Representative's Warrant Agreement, upon delivery will have been
 duly executed by the Company and, when delivered in accordance with the terms hereof, will
 constitute the valid and binding obligation of the Company enforceable against the Company
 in accordance with its terms, except (i) as limited by general equitable principles and applicable
 bankruptcy, insolvency, reorganization, moratorium and other laws of general application
 affecting enforcement of creditors' rights generally, (ii) as limited by laws relating
 to the availability of specific performance, injunctive relief or other equitable remedies
 and (iii) insofar as indemnification and contribution provisions may be limited by applicable
 law.

2.4.5  **<u>No Conflicts</u>** . The execution, delivery and performance by the Company of this Agreement
 and the Representative's Warrant Agreement, and the issuance and sale of the Shares
 and the consummation by it of the transactions contemplated hereby and thereby do not and
 will not (i) conflict with or violate any provision of the Company's certificate or
 articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict
 with, or constitute a default (or an event that with notice or lapse of time or both would
 become a default) under, result in the creation of any Lien upon any of the properties or
 assets of the Company, or give to others any rights of termination, amendment, anti-dilution
 or similar adjustments, acceleration or cancellation (with or without notice, lapse of time
 or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company
 debt or otherwise) or other understanding to which the Company is a party or by which any
 property or asset of the Company is bound or affected, or (iii) subject to the Required Approvals,
 conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
 decree or other restriction of any court or governmental authority to which the Company is
 subject, or by which any property or asset of the Company is bound or affected; except in
 the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected
 to result in a Material Adverse Effect.

2.4.6  **<u>Filings, Consents and Approvals</u>** . The Company is not required to obtain any consent, waiver,
 authorization or order of, give any notice to, or make any filing or registration with, any
 court or other federal, state, local or other governmental authority or other Person in connection
 with the execution, delivery and performance by the Company of this Agreement, the Representative's
 Warrant Agreement, the consummation of the transactions contemplated hereby, the application
 of the proceeds from the sale of the Shares as described under "Use of Proceeds"
 in the most recent Preliminary Prospectus, other than: (i) the Registration of the Shares
 under the Securities Act; (ii) the listing of the Shares on the Exchange; (iii) such consents,
 approvals, authorizations, orders, filings, registrations or qualifications as may be registered
 under the Exchange Act and applicable state or foreign securities laws and/or the bylaws
 and rules of the Financial Industry Regulatory Authority ()"**FINRA**") in
 connection with the purchase and sale of the Shares by the Underwriters; and (iv) such consents,
 approvals, authorizations, orders, filings, registrations or qualifications, which, if not
 obtained, would not, individually or in the aggregate, reasonably be expected to result in
 a Material Adverse Effect (collectively, the "**Required Approvals** ").

2.4.7  **<u>Issuance of the Shares; Registration</u>** . The Shares and the Representative's Warrant Shares
 are duly authorized and, when issued and paid for in accordance with this Agreement and the
 Representative's Warrant Agreement, will be duly and validly issued, fully paid and
 nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved
 from its duly authorized capitalization the maximum number of shares of Common Stock issuable
 pursuant to this Agreement and the Representative's Warrant Agreement.

2.4.8  **<u>Capitalization</u>** .
 The equity capitalization of the Company is as set forth in the Registration Statement and
 the Prospectus for the dates so identified under the caption "Capitalization"
 (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon
 the exercise of outstanding options or warrants, in each case described in the Registration
 Statement and the Prospectus). No Person has any right of first refusal, preemptive right,
 right of participation, or any similar right to participate in the transactions contemplated
 by this Agreement and the Representative's Warrant Agreement. Except as set forth in
 the Registration Statement and the Prospectus, there are no outstanding options, warrants,
 rights to subscribe to, calls or commitments of any character whatsoever relating to, or
 securities, rights or obligations convertible into or exercisable or exchangeable for, or
 giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts,
 commitments, understandings or arrangements by which the Company is or may become bound to
 issue additional shares of Common Stock. Except as described in the Registration Statement
 and the Prospectus, the issuance and sale of the Shares will not obligate the Company to
 issue shares of Common Stock or other securities to any Person (other than the Underwriters)
 and will not result in a right of any holder of Company securities to adjust the exercise,
 conversion, exchange or reset price under any of such securities. There are no outstanding
 securities or instruments of the Company that contain any redemption or similar provisions,
 and there are no contracts, commitments, understandings or arrangements by which the Company
 is or may become bound to redeem a security of the Company. All of the outstanding shares
 of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
 have been issued in compliance with the applicable federal, state, local and foreign securities
 laws, and none of such outstanding shares was issued in violation of any preemptive rights
 or similar rights to subscribe for or purchase securities. Except for the Required Approvals,
 no further approval or authorization of any shareholder, the Board of Directors or others
 is required for the issuance and sale of the Shares. Except as disclosed in the Registration
 Statement, there are no shareholders agreements, voting agreements or other similar agreements
 with respect to the Company's capital stock to which the Company is a party or, to
 the knowledge of the Company, between or among any of the Company's shareholders.

2.4.9  **<u>Financial Statements</u>** . The financial statements of the Company, together with related notes
 as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
 comply in all material respects with the applicable requirements of the Securities Act and
 present fairly in all material respects the financial position and the results of operations
 and cash flows of the Company, at the indicated dates and for the indicated periods. Such
 financial statements and related schedules have been prepared in accordance with United States
 generally accepted accounting principles ()"**GAAP** "), consistently applied
 throughout the periods involved, except as disclosed therein, and all adjustments necessary
 for a fair presentation of results for such periods have been made. The summary financial
 presentation included in the Registration Statement, the Pricing Disclosure Package and the
 Prospectus present fairly in all material respects the information shown therein and such
 data has been compiled on a basis consistent with the financial statements presented therein
 and the books and records of the Company. If applicable, all disclosures contained in the
 Registration Statement, the Pricing Disclosure Package and the Prospectus regarding "non-GAAP
 financial measures" comply with Regulation G of the Exchange Act and Item 10 of Regulation
 S-K under the Securities Act, to the extent applicable. The Company does not have any material
 liabilities or obligations, direct or contingent (including any off-balance sheet obligations,
 not disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
 There are no financial statements (historical or pro forma) that are required to be included
 in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are
 not included as required.

2.4.10  **<u>Material Changes; Undisclosed Events, Liabilities or Developments</u>** . Since the date of the latest
 audited financial statements included within the Registration Statement, the Pricing Disclosure
 Package and the Prospectus, (i) there has been no event, occurrence or development that has
 had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the
 Company has not incurred any liabilities (contingent or otherwise) that are material, individually
 or in the aggregate, to the Company, or has entered into any transactions not in the ordinary
 course of business other than (A) trade payables and accrued expenses incurred in the ordinary
 course of business consistent with past practice and (B) liabilities not required to be reflected
 in the Company's financial statements pursuant to GAAP, (iii) the Company has not altered
 its method of accounting, (iv) the Company has not declared or made any dividend or distribution
 of cash or other property to its shareholders or purchased, redeemed or made any agreements
 to purchase or redeem any shares of its capital stock and (v) the Company has not issued
 any equity securities to any officer, director or Affiliate, except pursuant to existing
 Company stock option plans, except in each case as otherwise disclosed in the Registration
 Statement, the Pricing Disclosure Package and the Prospectus.

2.4.11  **<u>Litigation</u>** .
 Except as set forth in the Registration Statement, there is no action, suit, inquiry, notice
 of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
 against or affecting the Company or any of their respective properties before or by any court,
 arbitrator, governmental or administrative agency or regulatory authority (federal, state,
 county, local or foreign) (collectively, an "**Action**") which (i) adversely
 affects or challenges the legality, validity or enforceability of any of this Agreement,
 the Representative's Warrant Agreement or the Shares or (ii) could, if there were an
 unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.
 Except as set forth in the Registration Statement, neither the Company, nor any director
 or officer thereof, is or has been the subject of any Action involving a claim of violation
 of or liability under federal or state securities laws or a claim of breach of fiduciary
 duty, which could result in a Material Adverse Effect. There has not been, and to the knowledge
 of the Company, there is not pending or contemplated, any investigation by the Commission
 involving the Company or any current or former director or officer of the Company.

2.4.12  **<u>Labor Relations</u>** . Other than as disclosed in the Registration Statement, no labor dispute
 exists or, to the knowledge of the Company, is imminent with respect to any of the employees
 of the Company, which could reasonably be expected to result in a Material Adverse Effect.
 Other than as disclosed in the Registration Statement, none of the Company's employees
 is a member of a union that relates to such employee's relationship with the Company,
 and the Company is not a party to a collective bargaining agreement, and the Company believes
 that its relationships with its employees are good. The Company is in compliance with all
 applicable federal, state, local and foreign laws and regulations relating to employment
 and employment practices, terms and conditions of employment and wages and hours, except
 where the failure to be in compliance could not, individually or in the aggregate, reasonably
 be expected to have a Material Adverse Effect.

2.4.13  **<u>Compliance</u>** .
 The Company: (i) is and at all times has been in compliance with all statutes, rules, or
 regulations applicable to the Company's business, including but not limited to laws
 related to environmental protection, occupational health and safety, product quality and
 safety, employment and labor matters, exploration, mining and related activities ()"**Applicable Laws** "), except as could not, individually or in the aggregate, reasonably be expected
 to have a Material Adverse Effect; (ii) has not received any written notice of adverse finding,
 warning letter, untitled letter or other written notice from any governmental authority alleging
 or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals,
 clearances, authorizations, permits and supplements or amendments thereto required by any
 such Applicable Laws ()"**Authorizations** "); (iii) possesses all material
 Authorizations and such Authorizations are valid and in full force and effect and are not
 in material violation of any term of any such Authorizations; (iv) has not received written
 notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
 or other action from any governmental authority or third party alleging that any product
 operation or activity is in violation of any Applicable Laws or Authorizations and have no
 knowledge that any such governmental authority or third party is considering any such claim,
 litigation, arbitration, action, suit, investigation or proceeding, except as could not,
 individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;
 (v) has not received written notice that any governmental authority has taken, is taking
 or intends to take action to limit, suspend, modify or revoke any Authorizations and have
 no knowledge that any such governmental authority is considering such action, except as could
 not, individually or in the aggregate, reasonably be expected to have a Material Adverse
 Effect; and (vi) has filed, obtained, maintained or submitted all material reports, documents,
 forms, notices, applications, records, claims, submissions and supplements or amendments
 as required by any Applicable Laws or Authorizations and that all such reports, documents,
 forms, notices, applications, records, claims, submissions and supplements or amendments
 were complete and correct in all material respects on the date filed (or were corrected or
 supplemented by a subsequent submission).

2.4.14  **<u>Environmental Laws</u>** . Other than as disclosed in the Registration Statement, the Company (i) is in
 material compliance with all material federal, state, local and foreign laws relating to
 pollution or protection of human health or the environment (including ambient air, surface
 water, groundwater, land surface or subsurface strata), including laws relating to emissions,
 discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic
 or hazardous substances or wastes (collectively, "**Hazardous Materials** ")
 into the environment, or otherwise relating to the manufacture, processing, distribution,
 use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
 as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
 licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered,
 promulgated or approved thereunder ()"**Environmental Laws** "); (ii) has received
 all permits licenses or other approvals required of them under applicable Environmental Laws
 for their respective businesses; and (iii) is in compliance with all terms and conditions
 of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure
 to so comply could be reasonably expected to have, individually or in the aggregate, a Material
 Adverse Effect.

2.4.15  **<u>Regulatory Permits</u>** . The Company and all Subsidiaries possess all certificates, authorizations
 and permits issued by the appropriate federal, state, local or foreign regulatory authorities
 necessary to conduct their respective businesses as described in the Registration Statement,
 Pricing Disclosure Package and the Prospectus, except where the failure to possess such permits
 could not reasonably be expected to result in a Material Adverse Effect ()"**Material Permits** "), and the Company (or the applicable Subsidiary) has not received any
 notice of proceedings relating to the revocation or modification of any Material Permit.

2.4.16  **<u>Title to Assets</u>** . The Company has good and marketable title in fee simple to all real property
 owned by them and good and marketable title in all personal property owned by them that is
 material to the business of the Company, in each case free and clear of all Liens, including
 all the real property, personal property and other assets, including all interests in mining
 claims, mining leases, concessions, exploitation or extraction rights, or other property
 interests or rights or similar rights ()"**Mining Claims**") that are material
 to the respective businesses of the Company and the Subsidiaries as currently conducted,
 except for (i) Liens as do not materially affect the value of such property and do not materially
 interfere with the use made and proposed to be made of such property by the Company and (ii)
 Liens for the payment of federal, state or other taxes, for which appropriate reserves have
 been made therefor in accordance with GAAP and, the payment of which is neither delinquent
 nor subject to penalties. Any real property and facilities held under lease by the Company
 is held by them under valid, subsisting and enforceable leases with which the Company is
 in compliance in all material respects. All material Mining Claims in which the Company or
 any of the Subsidiaries has an interest or right are valid, subsisting and enforceable. Except
 as otherwise disclosed in the Registration Statement and Prospectuses, there are no expropriations
 or similar proceedings or any challenges to title or ownership of which the Company or the
 Subsidiaries have received notice against the Mining Claims or any part thereof and, to the
 knowledge of the Company, no such expropriations, proceedings or challenges are contemplated.
 Neither the Company nor any of its subsidiaries has any obligation to pay any royalty that
 is material to the Company and its subsidiaries as a whole in respect of any Mining Claims
 except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus.
 Except as disclosed in the Registration Statement, Pricing Disclosure Package and the Prospectus,
 there are no restrictions on the ability of the Company and the Subsidiaries to use, transfer
 or otherwise exploit any such Mining Claims except as required by applicable law or security
 instruments, except where such restrictions would not reasonably be expected to result in
 a Material Adverse Effect.

2.4.17  **<u>Intellectual Property</u>** . The Company has, or has rights to use, all patents, patent applications,
 trademarks, trademark applications, service marks, trade names, trade secrets, inventions,
 copyrights, licenses and other intellectual property rights and similar rights necessary
 or required for use in connection with their respective businesses as described in the Registration
 Statement, Pricing Disclosure Package and the Prospectus and which the failure to so have
 could have a Material Adverse Effect (collectively, the "**Intellectual Property Rights** ").
 None of, and the Company has not received a notice (written or otherwise) that any of, the
 Intellectual Property Rights has expired, terminated or been abandoned, or is expected to
 expire or terminate or be abandoned, within two (2) years from the date of this Agreement
 except as would not reasonably be expected to have a Material Adverse Effect. The Company
 has not received, since the date of the latest audited financial statements included within
 the Registration Statement, Pricing Disclosure Package and the Prospectus, a written notice
 of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or
 infringe upon the rights of any Person, except as could not have or reasonably be expected
 to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
 Property Rights are enforceable and there is no existing infringement by another Person of
 any of the Intellectual Property Rights. The Company has taken reasonable security measures
 to protect the secrecy, confidentiality and value of all of their intellectual properties,
 except where failure to do so could not, individually or in the aggregate, reasonably be
 expected to have a Material Adverse Effect. The Company has no knowledge of any facts that
 would preclude it from having valid license rights or clear title to the Intellectual Property
 Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights
 or licenses to use all Intellectual Property Rights that are necessary to conduct its business.

2.4.18  **<u>Insurance</u>** .
 The Company is insured by insurers of recognized financial responsibility against such losses
 and risks and in such amounts as are prudent and customary in the businesses in which the
 Company is engaged, including, but not limited to, directors and officers insurance coverage.
 The Company has no reason to believe that it will not be able to renew its existing insurance
 coverage as and when such coverage expires or to obtain similar coverage from similar insurers
 as may be necessary to continue its business without a significant increase in cost.

2.4.19  **<u>Transactions With Affiliates and Employees</u>** . Except as set forth in the Registration Statement,
 none of the officers or directors of the Company and, to the knowledge of the Company, none
 of the employees of the Company is presently a party to any transaction with the Company
 (other than for services as employees, officers and directors), including any contract, agreement
 or other arrangement providing for the furnishing of services to or by, providing for rental
 of real or personal property to or from, providing for the borrowing of money from or lending
 of money to or otherwise requiring payments to or from any officer, director or such employee
 or, to the knowledge of the Company, any entity in which any officer, director, or any such
 employee has a substantial interest or is an officer, director, trustee, stockholder, member
 or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting
 fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company
 and (iii) other employee benefits, including stock option agreements under any stock option
 plan of the Company.

2.4.20  **<u>Sarbanes-Oxley; Internal Accounting Controls</u>** . The Company is in material compliance with any and
 all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the
 date hereof, and any and all applicable rules and regulations promulgated by the Commission
 thereunder that are effective as of the date hereof and as of the Closing Date. The Company
 maintains a system of internal accounting controls sufficient to provide reasonable assurance
 that: (i) transactions are executed in accordance with management's general or specific
 authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
 statements in conformity with generally accepted accounting principles and to maintain asset
 accountability, (iii) access to assets is permitted only in accordance with management's
 general or specific authorization, and (iv) the recorded accountability for assets is compared
 with the existing assets at reasonable intervals and appropriate action is taken with respect
 to any differences. The Company maintains disclosure controls and procedures (as such term
 is defined in Rule 13a 15(e) under the Exchange Act) that comply with the requirements of
 the Exchange Act; such disclosure controls and procedures have been designed to ensure that
 material information relating to the Company and its subsidiaries is made known to the Company's
 principal executive officer and principal financial officer by others within those entities;
 and such disclosure controls and procedures are effective. The Company's certifying
 officers have evaluated the effectiveness of the disclosure controls and procedures of the
 Company as of the end of the period covered by the latest audited financial statements included
 in the Registration Statement, Pricing Disclosure Package and the Prospectus (such date,
 the "**Evaluation Date** "). Since the Evaluation Date, there have been no
 changes in the internal control over financial reporting (as such term is defined in the
 Exchange Act) that have materially affected, or is reasonably likely to materially affect,
 the internal control over financial reporting of the Company.

2.4.21  **<u>Certain Fees</u>** . Except as set forth in the Registration Statement, Pricing Disclosure Package
 and the Prospectus, no brokerage or finder's fees or commissions are or will be payable
 by the Company to any broker, financial advisor or consultant, finder, Underwriter, investment
 banker, bank or other Person with respect to the transactions contemplated by this Agreement
 and the Representative's Warrant Agreement

2.4.22  **<u>Investment Company</u>** . The Company is not, and is not an Affiliate of, and immediately after receipt
 of payment for the Shares, will not be or be an Affiliate of, an "investment company"
 within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
 its business in a manner so that it will not become an "investment company" subject
 to registration under the Investment Company Act of 1940, as amended.

2.4.23  **<u>Registration Rights</u>** . Except as set forth in the Registration Statement, no Person has any right
 to cause the Company to effect the registration under the Securities Act of any securities
 of the Company.

2.4.24  **<u>Exchange Act Registration</u>** . The Form 8-A Registration Statement on Form 8-A in respect of the
 registration of the Common Stock, pursuant to Section 12 of the Exchange Act, was filed with
 the Commission on January 6, 2026, such Form 8-A Registration Statement in the form delivered
 to the Underwriters was declared effective by the Commission in such form; no other document
 with respect to such Form 8-A Registration Statement has theretofore been filed with the
 Commission. The Form 8-A Registration Statement complies in all material respects with the
 Exchange Act.

2.4.25  **<u>Disclosure</u>** .
 All of the disclosure furnished by or on behalf of the Company to the Underwriters regarding
 the Company, their respective businesses and the transactions contemplated hereby, is true
 and correct in all material respects and does not contain any untrue statement of a material
 fact or omit to state any material fact necessary in order to make the statements made therein,
 in the light of the circumstances under which they were made, not misleading. The press releases
 disseminated by the Company during the twelve months preceding the date of this Agreement
 taken as a whole do not contain any untrue statement of a material fact or omit to state
 a material fact required to be stated therein or necessary in order to make the statements
 therein, in the light of the circumstances under which they were made and when made, not
 misleading. The Company acknowledges and agrees that no Underwriter makes or has made any
 representations or warranties with respect to the transactions contemplated hereby other
 than those specifically set forth in Section 3.2 hereof.

2.4.26  **<u>No Integrated Offering</u>** . Assuming the accuracy of the Underwriters' representations
 and warranties related thereto, neither the Company, nor any of its Affiliates, nor any Person
 acting on its or their behalf has, directly or indirectly, made any offers or sales of any
 security or solicited any offers to buy any security, under circumstances that would cause
 this offering of the Shares to be integrated with prior offerings by the Company for purposes
 of the Securities Act that would require the registration of any such securities under the
 Securities Act.

2.4.27  **<u>Foreign Private Issuer</u>** . The Company is a "foreign private issuer" within the
 meaning of Rule 405 under the Securities Act.

2.4.28  **<u>Tax Status</u>** . Except for matters that would not, individually or in the aggregate, have
 or reasonably be expected to result in a Material Adverse Effect, the Company (i) has made
 or filed all federal, state and local income and all foreign tax returns, reports and declarations
 required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental
 assessments and charges that are material in amount, shown or determined to be due on such
 returns, reports and declarations and (iii) has set aside on its books provision reasonably
 adequate for the payment of all material taxes for periods subsequent to the periods to which
 such returns, reports or declarations apply. There are no unpaid taxes in any material amount
 claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
 know of no basis for any such claim.

2.4.29  **<u>Foreign Corrupt Practices</u>** . Neither the Company, nor to the knowledge of the Company, any
 agent or other person acting on behalf of the Company, has (i) directly or indirectly, used
 any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related
 to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic
 government officials or employees or to any foreign or domestic political parties or campaigns
 from corporate funds, (iii) failed to disclose fully any contribution made by the Company
 (or made by any person acting on its behalf of which the Company is aware) which is in violation
 of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices
 Act.

2.4.30  **<u>Accountants</u>** .
 The Company's independent registered public accounting firm is as set forth in the
 Prospectus. Such accounting firm is a registered independent public accounting firm as required
 by the Securities Act and the rules and regulations promulgated thereunder.

2.4.31  **<u>Acknowledgment Regarding Underwriters' Purchase of Shares</u>** . The Company acknowledges and agrees
 that each of the Underwriters is acting solely in the capacity of an arm's length purchaser
 with respect to this Agreement and the Representative's Warrant Agreement and the transactions
 contemplated hereby. The Company further acknowledges that no Underwriter is acting as a
 financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
 this Agreement and the transactions contemplated hereby and any advice given by any Underwriter
 or any of their respective representatives or agents in connection with this Agreement and
 the Representative's Warrant Agreement and the transactions contemplated hereby is
 merely incidental to the Underwriters' purchase of the Shares. The Company further
 represents to each Underwriter that the Company's decision to enter into this Agreement
 and the Representative's Warrant Agreement has been based solely on the independent
 evaluation of the transactions contemplated hereby by the Company and its representatives.

2.4.32  **<u>Regulation M Compliance</u>** . The Company has not, and to its knowledge no one acting on its behalf
 has, (i) taken, directly or indirectly, any action designed to cause or to result in the
 stabilization or manipulation of the price of any security of the Company to facilitate the
 sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation
 for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person
 any compensation for soliciting another to purchase any other securities of the Company,
 other than, in the case of clauses (ii) and (iii), compensation paid to the Company's
 Underwriter in connection with the placement of the Shares.

2.4.33  **<u>Statistical Information</u>** . The statistical and market and industry-related data included in the
 Registration Statement, Pricing Disclosure Package and Prospectus are based on or derived
 from sources which the Company reasonably believes to be reliable and accurate or represent
 the Company's good faith estimates that are made on the basis of data derived from
 such sources and the Company has obtained the written consent to the use of such data from
 sources to the extent required.

2.4.34  **<u>Technical Matters</u>** . All scientific and technical information set forth in the Registration Statement,
 the Pricing Disclosure Package and the Prospectus relating to any mining properties that
 are material to the Company has been prepared in accordance in all material respects with
 the standards set forth in in subpart 1300 of the Commission's Regulation S K of the
 Securities Act and, to the knowledge of the Company, there have been no material changes
 to such information since the date of delivery or preparation thereof, except as disclosed
 or included in the Registration Statement, Pricing Disclosure Package and Prospectus.

2.4.35  **<u>Office of Foreign Assets Control</u>** . Neither the Company nor, to the Company's knowledge,
 any director, officer, agent, employee or affiliate of the Company is currently subject to
 any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury
 Department ()"**OFAC**") and the Company will not, directly or indirectly,
 use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
 such proceeds to any subsidiary, joint venture partner or other person or entity, for the
 purpose of financing the activities of any person currently subject to any U.S. sanctions
 administered by OFAC.

2.4.36  **<u>U.S. Real Property Holding Corporation</u>** . The Company is not and has never been a U.S. real
 property holding corporation within the meaning of Section 897 of the Internal Revenue Code
 of 1986, as amended, and the Company shall so certify upon Underwriter's request.

2.4.37  **<u>Bank Holding Company Act</u>** . Neither the Company nor any of its Affiliates is subject to
 the Bank Holding Company Act of 1956, as amended (the "**BHCA**") and to regulation
 by the Board of Governors of the Federal Reserve System (the "**Federal Reserve** ").
 Neither the Company nor any of its Affiliates owns or controls, directly or indirectly, five
 percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five
 percent or more of the total equity of a bank or any entity that is subject to the BHCA and
 to regulation by the Federal Reserve. Neither the Company nor any of its Affiliates exercises
 a controlling influence over the management or policies of a bank or any entity that is subject
 to the BHCA and to regulation by the Federal Reserve.

2.4.38  **<u>Money Laundering</u>** . The operations of the Company are and have been conducted at all times
 in compliance with applicable financial record-keeping and reporting requirements of the
 Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering
 statutes and applicable rules and regulations thereunder (collectively, the "**Money Laundering Laws** "), and no action, suit or proceeding by or before any court or
 governmental agency, authority or body or any arbitrator involving the Company with respect
 to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

2.4.39  **<u>PFIC Status</u>** . The Company does not believe it is a Passive Foreign Investment Company ()"**PFIC** ")
 within the meaning of Section 1296 of the United States Internal Revenue Code of 1986, as
 amended, and does not believe it is likely to become a PFIC.

2.4.40  **<u>Stamp or Other Tax</u>** . No stamp or other issuance or transfer taxes or duties and no capital
 gains, income, withholding or other taxes are payable by or on behalf of any Underwriter
 to any political subdivision or taxing authority thereof or therein in connection with the
 sale and delivery by the Company of the Shares to or for the sale and delivery by Shares
 to the Underwriters.

2.4.41  **<u>Lock-Up Agreements</u>** . <u>Schedule 3</u> hereto contains a complete and accurate list of the
 Company's officers, directors and 5% or greater shareholders (collectively, the "**Lock-Up Parties** "). The Company has caused each of the Lock-Up Parties to deliver to the
 Representatives an executed Lock-Up Agreement, in the form attached hereto as <u>Exhibit B</u> (the "**Lock-Up Agreement** "), with the lock-up period listed on Schedule
 3, prior to the execution of this Agreement.

---

| | |
|:---|:---|
| 3 | **<u>Covenants of the Company</u>** |

---

The Company covenants and agrees as follows:

3.1  **<u>Amendments to Registration Statement</u>** . The Company shall deliver to the Representative, prior
 to filing, any amendment or supplement to the Registration Statement, the Preliminary Prospectus,
 the Pricing Disclosure Package or Prospectus proposed to be filed after the date of this
 Agreement and not file any such amendment or supplement to which the Representatives
 shall reasonably object in writing.

3.2  **<u>Federal Securities Laws</u>** 

3.2.1  **<u>Compliance</u>** .
 The Company, subject to <u>Section 3.2.2</u>, shall comply with the requirements of Rule
 424(b) and Rule 430A of the Securities Act Regulations, and will notify the Representatives
 promptly, and confirm the notice in writing, (i) when any post-effective amendment to the
 Registration Statement or any amendment or supplement to any Preliminary Prospectus, the
 Pricing Disclosure Package or the Prospectus shall have been filed and when any post-effective
 amendment to the Registration Statement shall become effective; (ii) of the receipt of any
 comments from the Commission; (iii) of any request by the Commission for any amendment to
 the Registration Statement or any amendment or supplement to any Preliminary Prospectus,
 the Pricing Disclosure Package or the Prospectus, or for additional information; (iv) of
 the issuance by the Commission of any stop order suspending the effectiveness of the Registration
 Statement or any post-effective amendment or of any order preventing or suspending the use
 of any Preliminary Prospectus, the Pricing Disclosure Package or the Prospectus, or of the
 suspension of the qualification of the Shares for offering or sale in any jurisdiction, or
 of the initiation or threatening of any proceedings for any of such purposes or of any examination
 pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement
 and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities
 Act in connection with the Offering of the Shares. The Company shall effect all filings required
 under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period
 required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as
 it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing
 under Rule 424(b) was received for filing by the Commission and, in the event that it was
 not, it will promptly file such prospectus. The Company shall use commercially reasonable
 efforts to prevent the issuance of any stop order, prevention or suspension and, if any such
 order is issued, to obtain the lifting thereof at the earliest possible moment.

3.2.2  **<u>Continued Compliance</u>** . The Company shall comply with the Securities Act, the Securities Act
 Regulations, the Exchange Act and the rules and regulations of the Commission promulgated
 under the Exchange Act (the "**Exchange Act Regulations**") so as to permit
 the completion of the distribution of the Shares as contemplated in this Agreement and in
 the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any
 time when a prospectus relating to the Shares is (or, but for the exception afforded by Rule
 172 of the Securities Act Regulations ()"**Rule 172** "), would be) required
 by the Securities Act to be delivered in connection with sales of the Shares, any event shall
 occur or condition shall exist as a result of which it is necessary, in the opinion of counsel
 for the Underwriters or for the Company, to (i) amend the Registration Statement in order
 that the Registration Statement will not include an untrue statement of a material fact or
 omit to state a material fact required to be stated therein or necessary to make the statements
 therein not misleading; (ii) amend or supplement the Pricing Disclosure Package or the Prospectus
 in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will
 not include any untrue statement of a material fact or omit to state a material fact necessary
 in order to make the statements therein not misleading in the light of the circumstances
 existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement
 or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may
 be, in order to comply with the requirements of the Securities Act or the Securities Act
 Regulations, the Company will promptly (A) give the Representatives notice of such
 event; (B) prepare any amendment or supplement as may be necessary to correct such statement
 or omission or to make the Registration Statement, the Pricing Disclosure Package or the
 Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed
 filing or use, furnish the Representatives with copies of any such amendment or supplement
 and (C) file with the Commission any such amendment or supplement; provided that the Company
 shall not file or use any such amendment or supplement to which the Representatives
 or counsel for the Underwriters shall reasonably object. The Company will furnish to the
 Underwriters such number of copies of such amendment or supplement as the Underwriters may
 reasonably request. The Company shall give the Representatives notice of its intention
 to make any filing pursuant to the Exchange Act or the Exchange Act Regulations from the
 Applicable Time until the later of the Closing Date and the exercise in full or expiration
 of the Over-Allotment Option specified in Section 1.2 hereof and will furnish the Representatives
 with copies of the related document(s) a reasonable amount of time prior to such proposed
 filing, as the case may be, and will not file or use any such document to which the Representatives
 or counsel for the Underwriters shall reasonably object.

3.3  **<u>Delivery to the Underwriters of Registration Statements</u>** . The Company has delivered or made
 available or shall deliver or make available to the Underwriters and counsel for the Representative,
 without charge, signed copies of the Registration Statement as originally filed and each
 amendment thereto (including exhibits filed therewith or incorporated by reference therein)
 and signed copies of all consents and certificates of experts, and will also deliver to the
 Underwriters, without charge, a conformed copy of the Registration Statement as originally
 filed and each amendment thereto (without exhibits) for each of the Underwriters. The copies
 of the Registration Statement and each amendment thereto furnished to the Underwriters will
 be identical to the electronically transmitted copies thereof filed with the Commission pursuant
 to EDGAR, except to the extent permitted by Regulation S-T.

3.4  **<u>Delivery to the Underwriters of Prospectuses</u>** . The Company has delivered or made available
 or will deliver or make available to each Underwriter, without charge, as many copies of
 each Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby
 consents to the use of such copies for purposes permitted by the Securities Act. The Company
 will furnish to each Underwriter, without charge, during the period when a prospectus relating
 to the Shares is (or, but for the exception afforded by Rule 172, would be) required to be
 delivered under the Securities Act, such number of copies of the Prospectus (as amended or
 supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments
 or supplements thereto furnished to the Underwriters will be identical to the electronically
 transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
 permitted by Regulation S-T.

3.5  **<u>Events Requiring Notice to the Representatives</u>** . The Company shall use commercially reasonable efforts to cause the Registration Statement
to remain effective with a current prospectus for at least nine (9) months after the Applicable Time, and shall notify the Representatives
promptly and confirm the notice in writing: (i) of the issuance by the Commission of any stop order or of the initiation, or the threatening,
of any proceeding for that purpose; (ii) of the issuance by any state securities commission of any proceedings for the suspension of
the qualification of the Shares for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding
for that purpose; (iii) of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement
or Prospectus; (iv) of the receipt of any comments or request for any additional information from the Commission; and (v) of the happening
of any event that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Pricing
Disclosure Package or the Prospectus untrue or that requires the making of any changes in (a) the Registration Statement in order to
make the statements therein not misleading, or (b) in the Pricing Disclosure Package or the Prospectus in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. If the Commission or any state securities commission
shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to obtain promptly
the lifting of such order.

3.6  **<u>Exchange Act Registration</u>** . For a period of three (3) years after the date of this Agreement,
 the Company shall use its best efforts to maintain the registration of the Common Stock under
 the Exchange Act. The Company shall not deregister the Common Stock under the Exchange Act
 for a period of three (3) years after the date of this Agreement without the prior written
 consent of the Underwriters, such consent not to be unreasonably withheld, provided, however,
 in the event of (i) a sale of the Company; (ii) sale of substantially all assets of the Company;
 or (iii) a transaction resulting in the purchase of all or substantially all Common Stock
 of the Company (in either event, a "**Fundamental Transaction** "), the foregoing
 covenant set forth in this Section 3.6 shall terminate; provided such deregistration is required
 to effect the Fundamental Transaction.

3.7  **<u>Free Writing Prospectuses</u>** . The Company agrees that, unless it obtains the prior written
 consent of the Representative, it shall not make any offer relating to the Shares that would
 constitute an Issuer Free Writing Prospectus or that would otherwise constitute a "free
 writing prospectus," or a portion thereof, required to be filed by the Company with
 the Commission or retained by the Company under Rule 433. The Company represents that it
 has treated or agrees that it will treat each such free writing prospectus consented to by
 the Underwriters as an "issuer free writing prospectus," as defined in Rule 433,
 and that it has complied and will comply with the applicable requirements of Rule 433 with
 respect thereto, including timely filing with the Commission where required, legending and
 record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there
 occurred or occurs an event or development as a result of which such Issuer Free Writing
 Prospectus conflicted or would conflict with the information contained in the Registration
 Statement or included or would include an untrue statement of a material fact or omitted
 or would omit to state a material fact necessary in order to make the statements therein,
 in the light of the circumstances existing at that subsequent time, not misleading, the Company
 will promptly notify the Underwriters and will promptly amend or supplement, at its own expense,
 such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement
 or omission.

3.8  **<u>Review of Financial Statements</u>** . For a period of three (3) years after the date of this Agreement,
 the Company, at its expense, shall cause its regularly engaged independent registered public
 accounting firm to review (but not audit) the Company's financial statements for the
 first six month of each fiscal year (or other periods required under the Commission's
 rules on financial statements) immediately preceding the announcement of any such six months
 (or other periods required) financial information, provided that such a provision shall not
 prevent a sale, merger or similar transaction involving the Company.

3.9  **<u>Listing</u>** .
 The Company shall use commercially reasonable efforts to maintain the listing of the Common
 Stock (including the Shares) on the Exchange for at least three years from the date of this
 Agreement.

3.10  **<u>Reports to the Representative</u>** .

3.10.1  **<u>Periodic Reports, etc.</u>** For a period of one year after the date of this Agreement, the Company
 shall furnish to the Representatives copies of such financial statements and other
 periodic and special reports as the Company from time to time furnishes generally to holders
 of any class of its securities and also promptly furnish to the Representative: (i)
 a copy of each periodic report the Company shall be required to file with the Commission
 under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press release
 and every news item and article with respect to the Company or its affairs which was released
 by the Company; (iii) a copy of each Form 6-K prepared and filed by the Company; (iv) five
 copies of each registration statement filed by the Company under the Securities Act; and
 (v) such additional documents and information with respect to the Company and the affairs
 of any future subsidiaries of the Company as the Representatives may from time to
 time reasonably request; provided the Representatives shall sign, if requested by
 the Company, a Regulation FD compliant confidentiality agreement which is reasonably acceptable
 to the Representatives and Representatives Counsel in connection with the Representatives'
 receipt of such information. Documents filed with the Commission pursuant to its EDGAR system
 shall be deemed to have been delivered to the Representatives pursuant to this Section
 3.10.1.

3.10.2  **<u>Transfer Agent</u>** . For a period of three (3) years after the date of this Agreement, the Company
 shall retain a transfer agent and registrar reasonably acceptable to the Representatives
 (the "**Transfer Agent**") and, for a period of one (1) year after the date
 of this Agreement, shall furnish to the Representatives such transfer sheets of the
 Company's securities as the Representatives may reasonably request, including
 the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Vstock
 Transfer, LLC is acceptable to the Representatives to act as Transfer Agent for the
 Common Stock.

3.11  **<u>Payment of Expenses</u>** . The Company agrees to pay on each of the Closing Date and the Option
 Closing Date, if any, all expenses incident to the performance of the obligations of the
 Company under this Agreement, including but not limited to (a) reasonable and documented
 fees and expenses of the Representative's legal counsel incurred in connection
 with the Offering in an amount up to $200,000 and (b) up to $20,000 of the Representative's
 non-accountable expenses, including, but not limited to, IPREO software related expenses,
 background check(s), tombstones, escrow agent fees, marketing-related expenses (i.e. roadshow,
 travel, etc.) and any other expenses incurred by the Representatives in connection
 with the transaction.

3.12  **<u>Application of Net Proceeds</u>** . The Company shall apply the net proceeds from the Offering received
 by it in a manner consistent with the application thereof described under the caption "Use
 of Proceeds" in the Registration Statement, the Pricing Disclosure Package and the
 Prospectus.

3.13  **<u>Exchange Act</u>** . The Company shall make generally available to its security holders as soon as
 practicable, but not later than the first day of the fifteenth (15th) full calendar month
 following the date of this Agreement, an earnings statement (which need not be certified
 by independent registered public accounting firm unless required by the Securities Act or
 the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under
 Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive
 months beginning after the date of this Agreement.

3.14  **<u>Stabilization</u>** .
 The Company will not take, and will use its commercially reasonable best efforts to cause
 its affiliates not to take, directly or indirectly, any action designed to or that has constituted
 or that might reasonably be expected to cause or result in, under Regulation M of the Exchange
 Act, or otherwise, stabilization or manipulation of the price of any security of the Company
 to facilitate the sale or resale of the Shares.

3.15  **<u>Internal Controls</u>** . The Company shall maintain a system of internal accounting controls sufficient
 to provide reasonable assurances that: (i) transactions are executed in accordance with management's
 general or specific authorization; (ii) transactions are recorded as necessary in order to
 permit preparation of financial statements in accordance with GAAP and to maintain accountability
 for assets; (iii) access to assets is permitted only in accordance with management's
 general or specific authorization; and (iv) the recorded accountability for assets is compared
 with existing assets at reasonable intervals and appropriate action is taken with respect
 to any differences.

3.16  **<u>Accountants</u>** .
 As of the date of this Agreement, the Company shall continue to retain a nationally recognized
 independent registered public accounting firm for a period of at least three (3) years after
 the date of this Agreement. The Underwriters acknowledge that Pipara & Co LLP (the "**Auditor** ")
 is acceptable to the Representative.

3.17  **<u>FINRA</u>** .
 The Company shall advise the Representatives (who shall make an appropriate filing
 with FINRA) if it is or becomes aware that Company or any of its affiliates (within the meaning
 of FINRA's Conduct Rule 5121(f)(1)) directly or indirectly controls, is controlled
 by, or is under common control with, or is an associated person (within the meaning of Article
 I, Section 1(ee) of the By-laws of FINRA) of, any member firm of FINRA.

3.18  **<u>Company Lock-Up Agreements</u>** .

3.18.1  **<u>Restriction on Sales of Shares</u>** . The Company, on behalf of itself and any successor entity, agrees
 that, without the prior written consent of the Representative, it will not, for a period
 of one hundred and eighty (180) days from the Closing Date (the "**Lock-Up Period** "),
 (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
 any option or contract to sell, grant any option, right or warrant to purchase, lend, or
 otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of
 the Company or any securities convertible into or exercisable or exchangeable for shares
 of capital stock of the Company; (ii) file or cause to be filed any registration statement
 with the Commission relating to the offering of any shares of capital stock of the Company
 or any securities convertible into or exercisable or exchangeable for shares of capital stock
 of the Company; or (iii) enter into any swap or other arrangement that transfers to another,
 in whole or in part, any of the economic consequences of ownership of capital stock of the
 Company, whether any such transaction described in clause (i), (ii) or (iii) above is to
 be settled by delivery of shares of capital stock of the Company or such other securities,
 in cash or otherwise. The restrictions contained in this Section 3.18.1 shall not apply to
 (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company of
 shares of Common Stock upon the exercise of a stock option or warrant or the conversion of
 a security outstanding on the date hereof, of which the Representatives has been advised
 in writing, provided that such securities outstanding on the date hereof have not been amended
 since the date of this Agreement to increase the number of such securities or to decrease
 the exercise price, exchange price or conversion price of such securities (other than in
 connection with stock splits or combinations) or to extend the term of such securities; (iii)
 the issuance by the Company of stock options or shares of capital stock of the Company under
 (A) any equity compensation plan of the Company to employees, officers, consultants or directors
 of the Company for services rendered to the Company or (B) any stock options issued or to
 be issued to certain shareholders of the Company as disclosed in the Prospectus; (iv) the
 transfer, issuance, sale or disposition of shares of Common Stock or any security convertible
 into or exercisable or exchangeable for shares of Common Stock pursuant to an investment
 in which a single strategic investor (and not an organization primarily engaged in the business
 of capital raising) that is, itself or through its subsidiaries, an operating company or
 an owner of an asset in a business synergistic with the business of the Company and shall
 provide to the Company additional benefits in addition to the investment of funds acquires
 over twenty five percent (25%) of the fully diluted capitalization of the date thereof, provided
 that such securities are issued as "restricted securities" (as defined in Rule
 144) and carry no registration rights that require or permit the filing of any registration
 statement in connection therewith during six (6) months following the Closing Date; or (v)
 shares of Common Stock or other securities issued in connection with a transaction with an
 unaffiliated third party that includes a bona fide commercial relationship entered into at
 arms-length (including joint ventures, marketing or distribution arrangements, collaboration
 agreements or intellectual property license agreements) or any acquisition of assets or acquisition
 of not less than a majority or controlling portion of the equity of another entity provided
 that any such transaction involves solely existing business segments or business scope that
 the Company is already operating in as described in the Registration Statement, the Pricing
 Disclosure Package or the Final Prospectus and provided that such shares of Common Stock
 or other securities are issued as "restricted securities" (as defined in Rule
 144) and carry no registration rights that require or permit the filing of any registration
 statement in connection therewith during six (6) months following the Closing Date.

3.18.2  **<u>Blue Sky Qualifications</u>** . The Company shall use its commercially reasonable efforts, in
 cooperation with the Underwriters, if necessary, to qualify the Shares for offering and sale
 under the applicable securities laws of such states and other jurisdictions (domestic or
 foreign) as either Representative may designate and to maintain such qualifications
 in effect so long as required to complete the distribution of the Shares; provided, however,
 that the Company shall not be obligated to file any general consent to service of process
 or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in
 which it is not so qualified or to subject itself to taxation in respect of doing business
 in any jurisdiction in which it is not otherwise so subject.

3.19  **<u>Reporting Requirements</u>** . The Company, during the period when a prospectus relating to the Shares
 is (or, but for the exception afforded by Rule 172, would be) required to be delivered under
 the Securities Act, will file all documents required to be filed with the Commission pursuant
 to the Exchange Act within the time periods required by the Exchange Act and Exchange Act
 Regulations. Additionally, the Company shall report the use of proceeds from the issuance
 of the Shares as may be required under Rule 463 under the Securities Act Regulations.

---

| | |
|:---|:---|
| 4 | **<u>Conditions of Underwriters' Obligations.</u>** |

---

The obligations of the Underwriters to purchase and pay for the Shares, as provided herein, shall be subject to (i) the continuing accuracy in all material respects of the representations and warranties of the Company as of the date hereof and as of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company in all material respects of its obligations hereunder; and (iv) the following condition

4.1  **<u>Regulatory Matters</u>** 

4.1.1  **<u>Effectiveness of Registration Statement; Required Filings</u>** . The Registration Statement has been
 declared effective by the Commission under the Securities Act and, at each of the Closing
 Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration
 Statement or any post-effective amendment thereto has been issued under the Securities Act,
 no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
 has been issued and no proceedings for any of those purposes have been instituted or are
 pending or, to the Company's knowledge, contemplated by the Commission. The Company
 has complied with each request (if any) from the Commission for additional information. The
 Prospectus containing the Rule 430A Information shall have been filed with the Commission
 in the manner and within the time frame required by Rule 424(b) (without reliance on Rule
 424(b)(8)) or a post-effective amendment providing such information shall have been filed
 with, and declared effective by, the Commission in accordance with the requirements of Rule
 430A under the Securities Act Regulations.

4.1.2  **<u>FINRA Clearance</u>** . On or before the date of this Agreement, the Representatives (as required)
 shall have received clearance from FINRA as to the amount of compensation allowable or payable
 to the Underwriters as described in the Registration Statement.

4.1.3  **<u>Exchange Stock Market Clearance</u>** . On the Closing Date, the Company's Common Stock, including
 the Firm Shares and the Option Shares, shall have been approved for listing on the Exchange,
 subject only to official notice of issuance.

4.2  **<u>Company Counsel Matters</u>** 

4.2.1  **<u>Closing Date Opinion of Counsel</u>** . On the Closing Date, the Underwriters shall have received
 the opinion and negative assurance letter of Disclosure Law Group, counsel to the Company,
 dated the Closing Date and addressed to the Representative, in form and substance reasonably
 satisfactory to the Representative.

4.2.2  **<u>Closing Date Opinion of Marshall Islands Counsel</u>** . On the Closing Date, the Underwriters shall
 have received the opinion of Holland & Knight LLP, New York, New York, Marshall Islands
 counsel to the Company, dated the Closing Date and addressed to the Representative, in form
 and substance reasonably satisfactory to the Representative.

4.2.3  **<u>Option Closing Date Opinion of Counsel</u>** . On the Option Closing Date, if any, the Underwriters
 shall have received the favorable opinions of such counsels listed in Sections 4.2.1 and
 4.2.2 dated as of the Option Closing Date, addressed to the Representatives and in
 form and substance reasonably satisfactory to the Representative, confirming as of the Option
 Closing Date, the statements made by such counsel in their respective opinion delivered on
 the Closing Date.

4.3  **<u>Comfort Letters</u>** 

4.3.1.1  **<u>Cold Comfort Letter</u>** . At the time this Agreement is executed, you shall have received a
 cold comfort letter containing statements and information of the type customarily included
 in accountants' comfort letters with respect to the financial statements and certain
 financial information contained in the Registration Statement, the Pricing Disclosure Package
 and the Prospectus, addressed to the Underwriters and in form and substance satisfactory
 in all respects to you and to the Auditor, dated as of the date of this Agreement.

4.3.1.2  **<u>Bring-down Comfort Letter</u>** . On the Closing Date and the Option Closing Date, you shall have received
 from the Auditor a letter, dated as of the Closing Date or the Option Closing Date, as applicable,
 to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant
 to Section 4.3.1, except that the specified date referred to shall be a date not more than
 three (3) business days prior to the Closing Date or the Option Closing Date, as applicable.

4.4  **<u>Officers' Certificates</u>** 

4.4.1  **<u>Officers' Certificate</u>** . The Company shall have furnished to the Underwriters a certificate,
 dated the Closing Date and any Option Closing Date (if such date is other than the Closing
 Date)), of its Chief Executive Officer, and its Chief Financial Officer stating that (i)
 such officers have carefully examined the Registration Statement, the Pricing Disclosure
 Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the
 Registration Statement and each amendment thereto, as of the Applicable Time and as of the
 Closing Date (or any Option Closing Date if such date is other than the Closing Date) did
 not include any untrue statement of a material fact and did not omit to state a material
 fact required to be stated therein or necessary to make the statements therein not misleading,
 and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date
 (or any Option Closing Date if such date is other than the Closing Date), any Issuer Free
 Writing Prospectus as of its date and as of the Closing Date (or any Option Closing Date
 if such date is other than the Closing Date), the Prospectus and each amendment or supplement
 thereto, as of the respective date thereof and as of the Closing Date (or any Option Closing
 Date if such date is other than the Closing Date), did not include any untrue statement of
 a material fact and did not omit to state a material fact necessary in order to make the
 statements therein, in the light of the circumstances in which they were made, not misleading,
 (ii) since the Applicable Time, no event has occurred which should have been set forth in
 a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or
 the Prospectus, (iii) to their knowledge after reasonable investigation, as of the Closing
 Date (or any Option Closing Date if such date is other than the Closing Date), the representations
 and warranties of the Company in this Agreement are true and correct in all material respects
 and the Company has complied with all agreements and satisfied all conditions on its part
 to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing
 Date if such date is other than the Closing Date), and (iv) there has not been, subsequent
 to the date of the most recent audited financial statements included in the Pricing Disclosure
 Package, any Material Adverse Effect in the financial position or results of operations of
 the Company, or any change or development that, singularly or in the aggregate, would involve
 a Material Adverse Effect, in or affecting the condition (financial or otherwise), results
 of operations, business, assets or prospects of the Company, except as set forth in the Prospectus.

4.4.2  **<u>Secretary's Certificate</u>** . At the Closing Date, and the Option Closing Date, if any, the Underwriters
 shall have received a certificate of the Company signed by the Secretary of the Company,
 dated the Closing Date or the Option Date, as the case may be, respectively, certifying:
 (i) that each of the Company's certificate or articles of incorporation, bylaws or
 other organizational or charter documents is true and complete, has not been modified and
 is in full force and effect; (ii) that the resolutions of the Company's Board of Directors
 relating to the Offering are in full force and effect and have not been modified; (iii) as
 to the accuracy and completeness of all correspondence between the Company or its counsel
 and the Commission; and (iv) as to the incumbency of the officers of the Company. The documents
 referred to in such certificate shall be attached to such certificate.

4.5  **<u>No Material Changes</u>** . Prior to and on the Closing Date and each Option Closing Date,
 if any: (i) there shall have been no Material Adverse Effect or development involving a prospective
 Material Adverse Effect in the condition or prospects or the business activities, financial
 or otherwise, of the Company from the latest dates as of which such condition is set forth
 in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii) no
 action, suit or proceeding, at law or in equity, shall have been pending or threatened against
 the Company or any director or officer before or by any court or federal, state, local or
 foreign commission, board or other administrative agency wherein an unfavorable decision,
 ruling or finding may materially adversely affect the business, operations, prospects or
 financial condition or income of the Company; (iii) no stop order shall have been issued
 under the Securities Act and no proceedings therefor shall have been initiated or threatened
 by the Commission; and (iv) the Registration Statement, the Pricing Disclosure Package and
 the Prospectus and any amendments or supplements thereto shall contain all material statements
 which are required to be stated therein in accordance with the Securities Act and the Securities
 Act Regulations and shall conform in all material respects to the requirements of the Securities
 Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing
 Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain
 any untrue statement of a material fact or omit to state any material fact required to be
 stated therein or necessary to make the statements therein, in the light of the circumstances
 under which they were made, not misleading.

4.6  **<u>No Material Misstatement or Omission</u>** . The Underwriters shall not have discovered and
 disclosed to the Company on or prior to the Closing Date and each Option Closing Date, if
 any, that the Registration Statement or any amendment or supplement thereto contains an untrue
 statement of a fact which, in the opinion of counsel for the Underwriters, is material or
 omits to state any fact which, in the opinion of such counsel, is material and is required
 to be stated therein or is necessary to make the statements therein not misleading, or that
 the Registration Statement, the Pricing Disclosure Package or the Prospectus or any amendment
 or supplement thereto contains an untrue statement of fact which, in the opinion of such
 counsel, is material or omits to state any fact which, in the opinion of such counsel, is
 material and is necessary in order to make the statements, in the light of the circumstances
 under which they were made, not misleading.

4.7  **<u>Delivery of Agreements</u>** 

4.7.1  **<u>Lock-Up Agreements</u>** . On or before the date of this Agreement, the Company shall have delivered
 to the Representatives executed copies of the Lock-Up Agreements from each of the
 persons listed in Schedule 3 hereto.

4.7.2  **<u>Representative's Warrant Agreement</u>** . On the Closing Date and on each Option Closing Date, the Company
 shall have delivered to A.G.P. (or its designees) executed copies of the Representative's
 Warrant Agreement.

4.8  **<u>Additional Documents</u>** . At the Closing Date and at each Option Closing Date (if any) Representatives
 Counsel shall have been furnished with such documents and opinions as they may reasonably
 require for the purpose of enabling Representatives Counsel to deliver an opinion
 to the Underwriters, or in order to evidence the accuracy of any of the representations or
 warranties, or the fulfillment of any of the conditions, herein contained; and all proceedings
 taken by the Company in connection with the issuance and sale of the Shares as herein contemplated
 shall be satisfactory in form and substance to the Representatives and Representatives
 Counsel.

---

| | |
|:---|:---|
| 5 | **<u>Indemnification</u>** |

---

5.1  **<u>Indemnification of the Underwriters</u>** 

5.1.1  **<u>General</u>** .
 Subject to the conditions set forth below, and to the extent permitted by law, the Company
 agrees to indemnify and hold harmless each Underwriter, its affiliates and each of their
 respective directors, officers, and employees, and each person, if any, who controls any
 such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of
 the Exchange Act (collectively the "**Underwriter Indemnified Parties**,"
 and each an "**Underwriter Indemnified Party** "), against any and all loss,
 liability, claim, damage and expense whatsoever (including but not limited to any and all
 legal or other expenses reasonably incurred in investigating, preparing or defending against
 any litigation, commenced or threatened, or any claim whatsoever, whether arising out of
 any action between any of the Underwriter Indemnified Parties and the Company or between
 any of the Underwriter Indemnified Parties and any third party, or otherwise) to which they
 or any of them may become subject under the Securities Act, the Exchange Act or any other
 statute or at common law or otherwise or under the laws of Marshall Islands, arising out
 of or based upon any untrue statement or alleged untrue statement of a material fact contained
 in (i) the Registration Statement, the Pricing Disclosure Package, the Preliminary Prospectus,
 or the Prospectus (as from time to time each may be amended and supplemented); (ii) any materials
 or information provided to investors by, or with the approval of, the Company in connection
 with the marketing of the Offering, including any "road show" or investor presentations
 made to investors by the Company (whether in person or electronically); or (iii) any application
 or other document or written communication (in this Section 5, collectively called "application")
 executed by the Company or based upon written information furnished by the Company in any
 jurisdiction in order to qualify the Shares under the securities laws thereof or filed with
 the Commission, any state securities commission or agency, the Exchange or any other national
 securities exchange; or the omission or alleged omission therefrom of a material fact required
 to be stated therein or necessary to make the statements therein, in the light of the circumstances
 under which they were made, not misleading, unless such statement or omission was made in
 reliance upon, and in conformity with, the Underwriters' Information. With respect
 to any untrue statement or omission or alleged untrue statement or omission made in the Pricing
 Disclosure Package, the indemnity agreement contained in this Section 5.1.1 shall not inure
 to the benefit of any Underwriter Indemnified Party to the extent that any loss, liability,
 claim, damage or expense of such Underwriter Indemnified Party results from the fact that
 a copy of the Prospectus was not given or sent to the person asserting any such loss, liability,
 claim or damage at or prior to the written confirmation of sale of the Shares to such person
 as required by the Securities Act and the Securities Act Regulations, and if the untrue statement
 or omission has been corrected in the Prospectus, unless such failure to deliver the Prospectus
 was a result of non-compliance by the Company with its obligations under Section 3.3 hereof.

5.1.2  **<u>Procedure</u>** .
 If any action is brought against an Underwriter Indemnified Party in respect of which indemnity
 may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified
 Party shall promptly notify the Company in writing of the institution of such action and
 the Company shall assume the defense of such action, including the employment and fees of
 counsel (subject to the reasonable approval of such Underwriter Indemnified Party) and payment
 of actual expenses. Such Underwriter Indemnified Party shall have the right to employ its
 or their own counsel in any such case, but the fees and expenses of such counsel shall be
 at the expense of such Underwriter Indemnified Party unless (i) the employment of such counsel
 at the expense of the Company shall have been authorized in writing by the Company in connection
 with the defense of such action, or (ii) the Company shall not have employed counsel to have
 charge of the defense of such action, or (iii) such indemnified party or parties shall have
 reasonably concluded that there may be defenses available to it or them which are different
 from or additional to those available to the Company (in which case the Company shall not
 have the right to direct the defense of such action on behalf of the indemnified party or
 parties), in any of which events the reasonable fees and expenses of not more than one additional
 firm of attorneys selected by the Underwriter Indemnified Party (in addition to local counsel)
 shall be borne by the Company. Notwithstanding anything to the contrary contained herein,
 if any Underwriter Indemnified Party shall assume the defense of such action as provided
 above, the Company shall have the right to approve the terms of any settlement of such action,
 which approval shall not be unreasonably withheld.

5.2  **<u>Indemnification of the Company</u>** . Each Underwriter, severally and not jointly, agrees to indemnify
 and hold harmless the Company, its directors, its officers who signed the Registration Statement
 and persons who control the Company within the meaning of Section 15 of the Securities Act
 or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and
 expense described in the foregoing indemnity from the Company to the several Underwriters,
 as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements
 or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing
 Disclosure Package or Prospectus or any amendment or supplement thereto or in any application,
 in reliance upon, and in strict conformity with, the Underwriters' Information. In
 case any action shall be brought against the Company or any other person so indemnified based
 on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package
 or Prospectus or any amendment or supplement thereto or any application, and in respect of
 which indemnity may be sought against any Underwriter, such Underwriter shall have the rights
 and duties given to the Company, and the Company and each other person so indemnified shall
 have the rights and duties given to the several Underwriters by the provisions of Section
 5.1.2. The Company agrees promptly to notify the Representatives of the commencement
 of any litigation or proceedings against the Company or any of its officers, directors or
 any person, if any, who controls the Company within the meaning of Section 15 of the Securities
 Act or Section 20 of the Exchange Act, in connection with the issuance and sale of the Shares
 or in connection with the Registration Statement, the Pricing Disclosure Package, or the
 Prospectus or any Issuer Free Writing Prospectus.

5.3  **<u>Contribution</u>** 

5.3.1  **<u>Contribution Rights</u>** . If the indemnification provided for in this Section 5 shall for any reason
 be unavailable to or insufficient to hold harmless an indemnified party under Section 5.1
 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof,
 referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified
 party, contribute to the amount paid or payable by such indemnified party as a result of
 such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion
 as shall be appropriate to reflect the relative benefits received by the Company, on the
 one hand, and the Underwriters, on the other, from the Offering of the Shares, or (ii) if
 the allocation provided by clause (i) above is not permitted by applicable law, in such proportion
 as is appropriate to reflect not only the relative benefits referred to in clause (i) above
 but also the relative fault of the Company, on the one hand, and the Underwriters, on the
 other, with respect to the statements or omissions that resulted in such loss, claim, damage
 or liability, or action in respect thereof, as well as any other relevant equitable considerations.
 The relative benefits received by the Company, on the one hand, and the Underwriters, on
 the other, with respect to such Offering shall be deemed to be in the same proportion as
 the total net proceeds from the Offering of the Shares purchased under this Agreement (before
 deducting expenses) received by the Company, as set forth in the table on the cover page
 of the Prospectus, on the one hand, and the total underwriting discounts and commissions
 received by the Underwriters with respect to the shares of Common Stock purchased under this
 Agreement, as set forth in the table on the cover page of the Prospectus, on the other hand.
 The relative fault shall be determined by reference to whether the untrue or alleged untrue
 statement of a material fact or omission or alleged omission to state a material fact relates
 to information supplied by the Company or the Underwriters, the intent of the parties and
 their relative knowledge, access to information and opportunity to correct or prevent such
 statement or omission. The Company and the Underwriters agree that it would not be just and
 equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata
 allocation (even if the Underwriters were treated as one entity for such purpose) or by any
 other method of allocation that does not take into account the equitable considerations referred
 to herein. The amount paid or payable by an indemnified party as a result of the loss, claim,
 damage or liability, or action in respect thereof, referred to above in this Section 5.3.1
 shall be deemed to include, for purposes of this Section 5.3.1, any legal or other expenses
 reasonably incurred by such indemnified party in connection with investigating or defending
 any such action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event
 shall an Underwriter be required to contribute any amount in excess of the amount by which
 the total underwriting discounts and commissions received by such Underwriter with respect
 to the Offering of the Shares exceeds the amount of any damages that such Underwriter has
 otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
 or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning
 of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
 who was not guilty of such fraudulent misrepresentation.

5.3.2  **<u>Contribution Procedure</u>** . Within fifteen (15) days after receipt by any party to this Agreement
 (or its representative) of notice of the commencement of any action, suit or proceeding,
 such party will, if a claim for contribution in respect thereof is to be made against another
 party ("contributing party"), notify the contributing party of the commencement
 thereof, but the failure to so notify the contributing party will not relieve it from any
 liability which it may have to any other party other than for contribution hereunder. In
 case any such action, suit or proceeding is brought against any party, and such party notifies
 a contributing party or its representative of the commencement thereof within the aforesaid
 15 days, the contributing party will be entitled to participate therein with the notifying
 party and any other contributing party similarly notified. Any such contributing party shall
 not be liable to any party seeking contribution on account of any settlement of any claim,
 action or proceeding affected by such party seeking contribution without the written consent
 of such contributing party. The contribution provisions contained in this Section 5.3.2 are
 intended to supersede, to the extent permitted by law, any right to contribution under the
 Securities Act, the Exchange Act or otherwise available. Each Underwriter's obligations
 to contribute pursuant to this Section 5.3 are several and not joint.

---

| | |
|:---|:---|
| 6 | **<u>Default by an Underwriter</u>** |

---

6.1  **<u>Default Not Exceeding 10% of Firm Shares or Option Shares</u>** . If any Underwriter or Underwriters
 shall default in its or their obligations to purchase the Firm Shares or the Option Shares,
 and if the number of the Firm Shares or the Option Shares with respect to which such default
 relates does not exceed in the aggregate 10% of the number of Firm Shares or the Option Shares
 that all Underwriters have agreed to purchase hereunder, then such Firm Shares or the Option
 Shares to which the default relates shall be purchased by the non-defaulting Underwriters
 in proportion to their respective commitments hereunder.

6.2  **<u>Default Exceeding 10% of Firm Shares or the Option Shares</u>** . In the event that the default
 addressed in Section 6.1 relates to more than 10% of the Firm Shares or the Option Shares,
 you may in your discretion arrange for yourself or for another party or parties to purchase
 such Firm Shares or the Option Shares to which such default relates on the terms contained
 herein. If, within one (1) Business Day after such default relating to more than 10% of the
 Firm Shares or the Option Shares, you do not arrange for the purchase of such Firm Shares
 or the Option Shares, then the Company shall be entitled to a further period of one (1) Business
 Day within which to procure another party or parties satisfactory to you to purchase said
 Firm Shares or the Option Shares on such terms. In the event that neither you nor the Company
 arrange for the purchase of the Firm Shares or the Option Shares to which a default relates
 as provided in this Section 6, this Agreement will automatically be terminated by you or
 the Company without liability on the part of the Company (except as provided in Sections
 3.11 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof);
 provided, however, that if such default occurs with respect to the Option Shares, this Agreement
 will not terminate as to the Firm Shares; and provided, further, that nothing herein shall
 relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and
 to the Company for damages occasioned by its default hereunder.

6.3  **<u>Postponement of Closing Date</u>** . In the event that the Firm Shares or Option Shares to which the
 default relates are to be purchased by the non-defaulting Underwriters, or are to be purchased
 by another party or parties as aforesaid, you or the Company shall have the right to postpone
 the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding
 five (5) Business Days, in order to effect whatever changes may thereby be made necessary
 in the Registration Statement, the Pricing Disclosure Package or the Prospectus or in any
 other documents and arrangements, and the Company agrees to file promptly any amendment to
 the Registration Statement, the Pricing Disclosure Package or the Prospectus that in the
 opinion of counsel for the Underwriters may thereby be made necessary. The term "Underwriter"
 as used in this Agreement shall include any party substituted under this Section 6 with like
 effect as if it had originally been a party to this Agreement with respect to such shares
 of Common Stock.

---

| | |
|:---|:---|
| 7 | **<u>Effective Date of this Agreement and Termination Thereof.</u>** |

---

7.1  **<u>Effective Date</u>** . This Agreement shall become effective when both the Company and the Representatives
 have executed the same and delivered counterparts of such signatures to the other party.

7.2  **<u>Termination</u>** .
 The Underwriters shall have the right to terminate this Agreement at any time prior to any
 Closing Date, (i) if any domestic or international event or act or occurrence has materially
 disrupted, or in the Representative's reasonable opinion will in the immediate future
 materially disrupt, general securities markets in the United States; or (ii) if trading on
 the New York Stock Exchange, the NYSE American LLC, the NASDAQ Capital Market, the NASDAQ
 Global Market, the NASDAQ Global Select Market shall have been suspended or materially limited,
 or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices
 for securities shall have been required by FINRA or by order of the Commission or any other
 government authority having jurisdiction; or (iii) if the United States shall have become
 involved in a new war or an increase in major hostilities; or (iv) if a banking moratorium
 has been declared by a New York State or federal authority; or (v) if a moratorium on foreign
 exchange trading has been declared which materially adversely impacts the United States securities
 markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident,
 hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether
 or not such loss shall have been insured, will, in the Representative's opinion, make
 it inadvisable to proceed with the delivery of the Firm Shares or Option Shares; (vii) if
 the Company is in material breach of any of its representations, warranties or covenants
 hereunder; or (viii) either Representatives shall have become aware after the date
 hereof of such a Material Adverse Effect in the conditions or prospects of the Company, or
 such adverse material change in general market conditions as in the Representative's
 judgment would make it impracticable to proceed with the offering, sale and/or delivery of
 the Shares or to enforce contracts made by the Underwriters for the sale of the Shares.

7.3  **<u>Expenses</u>** .
 Notwithstanding anything to the contrary in this Agreement, except in the case of a default
 by the Underwriters, pursuant to Section 6.2 above, in the event that this Agreement is terminated
 prior to the Closing Date for any reason whatsoever, within the time specified herein or
 any extensions thereof pursuant to the terms herein, the Company shall be obligated to pay
 to the Underwriters their actual and accountable out-of-pocket documented expenses related
 to the transactions contemplated herein then due and payable (including the out-of-pocket
 and documented fees and disbursements of Representatives Counsel) in the amounts set
 forth in Section 3 of the engagement letter, dated August 24, 2024, by and between the Company
 and the Representative, and upon demand the Company shall pay the full amount thereof up
 to the cap to the A.G.P./Alliance Global Partners on behalf of the Underwriters; provided,
 however, that such expense cap in no way limits or impairs the indemnification and contribution
 provisions of this Agreement.

7.4  **<u>Survival of Indemnification</u>** . Notwithstanding any contrary provision contained in this Agreement,
 any election hereunder or any termination of this Agreement, and whether or not this Agreement
 is otherwise carried out, the provisions of Section 5 shall remain in full force and effect
 and shall not be in any way affected by, such election or termination or failure to carry
 out the terms of this Agreement or any part hereof.

7.5  **<u>Representations, Warranties, Agreements to Survive</u>** . All representations, warranties and agreements
 contained in this Agreement or in certificates of officers of the Company submitted pursuant
 hereto, shall remain operative and in full force and effect regardless of (i) any investigation
 made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling
 any Underwriter, its officers or directors or any person controlling the Company or (ii)
 delivery of and payment for the Shares.

---

| | |
|:---|:---|
| 8 | **<u>Miscellaneous</u>** |

---

8.1  **<u>Notices</u>** .
 All communications hereunder, except as herein otherwise specifically provided, shall be
 in writing and shall be mailed (registered or certified mail, return receipt requested),
 personally delivered or sent by electronic mail (email) and confirmed and shall be deemed
 given when so delivered or sent via email and confirmed or if mailed, two (2) days after
 such mailing.

If to the Representatives:

A.G.P./Alliance Global Partners<br> 590 Madison Avenue, 28th Floor<br> New York, New York 10022<br> Attention: Thomas Higgins<br> Email: <u>thiggins@allianceg.com</u>

and to:

Banco Bradesco BBI S.A.

Avenida Juscelino Kubitschek, 1,309, 10<sup>th</sup> Floor<br> 04543-011, São Paulo, Brazil

Attention: Guilherme Zamai

Email: <u>guilherme.zamai@bradescobbi.com.br</u>

with a copy (which shall not constitute notice) to:

Blank Rome LLP

1271 Avenue of the America

New York, New York 1002

Attention: Leslie Marlow, Esq. or Patrick J. Egan, Esq.

Email: <u>leslie.marlow@blankrome.com</u>; <u>patrick.egan@blankrome.com</u>

If to the Company:

Atlas Critical Minerals Corporation

Rua Antônio de Albuquerque, 156, Suite 1720

Belo Horizonte, Minas Gerais, Brazil, 30112-010

Attention: Marc Fogassa, Chairman and Chief Executive Officer

Email: <u>mf@atlas-lithium.com</u>

with a copy (which shall not constitute notice) to:

Disclosure Law Group

600 West Broadway, Suite 700

San Diego, CA 92101

Attention: Daniel Rumsey, Esq

Email: <u>drumsey@disclosurelawgroup.com</u>

8.2  **<u>Headings</u>** .
 The headings contained herein are for the sole purpose of convenience of reference, and shall
 not in any way limit or affect the meaning or interpretation of any of the terms or provisions
 of this Agreement.

8.3  **<u>Amendment</u>** .
 This Agreement may only be amended by a written instrument executed by each of the parties
 hereto.

8.4  **<u>Entire Agreement</u>** . This Agreement (together with the other agreements and documents being
 delivered pursuant to or in connection with this Agreement) constitutes the entire agreement
 of the parties hereto with respect to the subject matter hereof and thereof, and supersedes
 all prior agreements and understandings of the parties, oral and written, with respect to
 the subject matter hereof.

8.5  **<u>Binding Effect</u>** . This Agreement shall inure solely to the benefit of and shall be binding
 upon the Representative, the Underwriters, the Company and the controlling persons, directors
 and officers referred to in Section 5 hereof, and their respective successors, legal representatives,
 heirs and assigns, and no other person shall have or be construed to have any legal or equitable
 right, remedy or claim under or in respect of or by virtue of this Agreement or any provisions
 herein contained. The term "successors and assigns" shall not include a purchaser,
 in its capacity as such, of securities from any of the Underwriters.

8.6  **<u>Governing Law; Consent to Jurisdiction; Trial by Jury; Service of Process</u>** . This Agreement shall
 be governed by and construed and enforced in accordance with the laws of the State of New
 York, without giving effect to conflict of laws principles thereof. The Company hereby agrees
 that any action, proceeding or claim against it arising out of, or relating in any way to
 this Agreement shall be brought and enforced in the New York Supreme Court, County of New
 York, or in the United States District Court for the Southern District of New York, and irrevocably
 submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives
 any objection to such exclusive jurisdiction and that such courts represent an inconvenient
 forum. Any such process or summons to be served upon the Company may be served by transmitting
 a copy thereof by registered or certified mail, return receipt requested, postage prepaid,
 addressed to it at the address set forth in Section 8.1 hereof. Such mailing shall be deemed
 personal service and shall be legal and binding upon the Company in any action, proceeding
 or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled
 to recover from the other party(ies) all of its reasonable attorneys' fees and expenses
 relating to such action or proceeding and/or incurred in connection with the preparation
 therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
 of its shareholders and affiliates) and each of the Underwriters hereby irrevocably waives,
 to the fullest extent permitted by applicable law, any and all right to trial by jury in
 any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
 hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Company hereby irrevocably designates and appoints the Trust Company of the Marshall Islands, Inc., with an office located at 60 East 42nd Street, Suite 1020, New York, New York 10165 (the "**Process Agent**"), as its authorized agent upon whom process may be served in any claim brought against the Company, it being understood that the designation and appointment of the Process Agent as such authorized agent shall become effective immediately without any further action on the part of the Company. The Company represents to each Underwriter that it has notified the Process Agent of such designation and appointment and that the Process Agent has accepted the same. The Company hereby irrevocably authorizes and directs the Process Agent to accept such service. The Company further agrees that service of process upon the Process Agent and written notice of said service to the Company, mailed by first-class mail and delivered to the Process Agent, shall be deemed in every respect effective service of process upon the Company in any such claim. Nothing herein shall affect the right of each Underwriter, its partners, directors, officers and members, any person who controls any Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, or any "affiliate" (within the meaning of Rule 405 under the Securities Act) of such Underwriter, or the successors and assigns of all of the foregoing persons, to serve process in any other manner permitted by law. The provisions of this Section 8.6 shall survive any termination of this Agreement, in whole or in part.

8.7  **<u>Judgment Currency</u>** . (i) If for the purpose of obtaining or enforcing judgment against the Company
 in any court in any jurisdiction it becomes necessary to convert into any other currency
 (such other currency being hereinafter in this Section 8.7 referred to as the "**Judgment Currency**") an amount due in U.S. Dollars under this Agreement, the conversion shall
 be made at the Exchange Rate prevailing on the Trading Day immediately preceding: (A) the
 date actual payment of the amount due, in the case of any proceeding in the courts of New
 York or in the courts of any other jurisdiction that will give effect to such conversion
 being made on such date or (B) the date on which the foreign court determines, in the case
 of any proceeding in the courts of any other jurisdiction (the date as of which such conversion
 is made pursuant to this Section 8.7 being hereinafter referred to as the "**Judgment Conversion Date** ").

 ****

8.8  **<u>Execution in Counterparts</u>** . This Agreement may be executed in one or more counterparts, and
 by the different parties hereto in separate counterparts, each of which shall be deemed to
 be an original, but all of which taken together shall constitute one and the same agreement,
 and shall become effective when one or more counterparts has been signed by each of the parties
 hereto and delivered to each of the other parties hereto. Delivery of a signed counterpart
 of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient
 delivery thereof.

8.9  **<u>Research Analyst Independence</u>** . The Company acknowledges that each Underwriter's research
 analysts and research departments are required to be independent from its investment banking
 division and are subject to certain regulations and internal policies, and that such Underwriter's
 research analysts may hold views and make statements or investment recommendations and/or
 publish research reports with respect to the Company and/or the Offering that differ from
 the views of their investment banking division. The Company acknowledges that each Underwriter
 is a full service securities firm and as such from time to time, subject to applicable securities
 laws, rules and regulations, may effect transactions for its own account or the account of
 its customers and hold long or short positions in debt or equity securities of the Company;
 provided, however, that nothing in this Section 8.9 shall relieve the Underwriter of any
 responsibility or liability it may otherwise bear in connection with activities in violation
 of applicable securities laws, rules or regulations.

 ****

8.10  **<u>Waiver, etc.</u>** The failure of any of the parties hereto to at any time to enforce any of the
 provisions of this Agreement shall not be deemed or construed to be a waiver of any such
 provision, nor to in any way effect the validity of this Agreement or any provision hereof
 or the right of any of the parties hereto to thereafter enforce each and every provision
 of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the
 provisions of this Agreement shall be effective unless set forth in a written instrument
 executed by the party or parties against whom or which enforcement of such waiver is sought;
 and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or
 deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

[*Signature page follows*]

If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **Atlas Critical Minerals Corporation** | **Atlas Critical Minerals Corporation** |
| By: | */s/ Marc Fogassa* |
| Name: | Marc Fogassa |
| Title: | Chief Executive Officer |

---

Confirmed as of the date first written above mentioned, on behalf of itself and as Representatives of the several Underwriters named on <u>Schedule 1</u> hereto:

---

| | |
|:---|:---|
| **A.G.P./ALLIANCE GLOBAL PARTNERS** | **A.G.P./ALLIANCE GLOBAL PARTNERS** |
| By: | */s/ Thomas J. Higgins* |
| Name: | Thomas J. Higgins |
| Title: | Managing Director |

---

---

| | |
|:---|:---|
| **BANCO BRADESCO BBI S.A.** | **BANCO BRADESCO BBI S.A.** |
| By: | */s/ Pedro Henrique Ney Oliveira* |
| Name: | Pedro Henrique Ney Oliveira |
| Title: | Director |
| By: | */s/ Sebastião Carlos de Camargo Junior* |
| Name: | Sebastião Carlos de Camargo Junior |
| Title: | Vice President |

---

[Signature Page to<br> Atlas Critical Minerals Corporation Underwriting Agreement]

**<u>SCHEDULE 1</u>**

---

| | | |
|:---|:---|:---|
| Underwriter | Total Number <br>of Firm <br>Shares to be <br>Purchased | Number of Option Shares to be Purchased if the Over-Allotment Option is Fully Exercised by the Representative |
| A.G.P./Alliance Global Partners | 840000 | 126000 |
| Banco Bradesco BBI S.A. | 360000 | 54000 |
| **Total** | **1200000** | **180000** |

---

Sch. 1-1

**<u>SCHEDULE 2-A</u>**

**Pricing Information**

Number of Firm Shares: 1,200,000

Number of Option Shares: 180,000

Public Offering Price per Firm Share: $8.00

Underwriting Discount per Firm Share sold to investors<sup>1</sup>: $0.56

Proceeds to Company per Firm Share (before expenses)<sup>2</sup>: $7.44

<sup>1</sup> The Underwriting discount per Firm Share for Company Introduced Investors is: $0.24.

<sup>2</sup> Proceeds to the Company per Firm Share (before expenses) for Company Introduced Investors is: $7.76.

Sch. 2-A-1

**<u>SCHEDULE 2-B</u>**

**Issuer General Use Free Writing Prospectus**

None.

Sch. 2-B-1

**<u>SCHEDULE 3</u>**

**List of Lock-Up Parties**

---

| | |
|:---|:---|
| **Lock-Up Parties** | **Term of Lock Up** |
| Marc Fogassa | 180 days |
| Rodrigo Nazareth Menck | 180 days |
| Joel de Paiva Monteiro, Esq. | 180 days |
| Areli Nogueira da Silva Júnior | 180 days |
| Brian W. Bernier | 180 days |
| Agenor Narcizo Drumond de Cuculicchio, Esq. | 180 days |
| Gabriel Santos Cordeiro de Andrade, Esq. | 180 days |
| Atlas Lithium Corporation | 180 days |

---

Sch. 3-1

**<u>EXHIBIT A</u>**

**Representative's Warrant Agreement**

**Form of Representative's Warrant Agreement**

**THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE COMMENCEMENT DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) A.G.P./ALLIANCE GLOBAL PARTNERS, OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF A.G.P./ALLIANCE GLOBAL PARTNERS OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.**

**THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO JULY 7, 2026 THE [DATE THAT IS 180 DAYS FROM THE COMMENCEMENT DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME, ON JULY 7, 2031 [THE DATE THAT IS FIVE YEARS FROM THE COMMENCEMENT DATE OF THE OFFERING].**

**COMMON STOCK PURCHASE WARRANT**

**ATLAS CRITICAL MINERALS CORPORATION**

Warrant Shares: _________<sup>1</sup> Original Issue Date: January 12, 2026

Initial Exercise Date: July 7, 2026

THIS COMMON STOCK PURCHASE WARRANT (the "<u>Warrant</u>") certifies that, for value received, _______or its assigns (the "<u>Holder</u>") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time from and after the 180th day from the date of effectiveness (the "<u>Commencement Date</u>") of that certain registration statement on Form F-1, as amended (File No. 333-290242) (the "<u>Registration Statement</u>"), filed by the Company (the "<u>Initial Exercise Date</u>"), in accordance with FINRA Rule 5110(e)(1), and through and including the five (5) year anniversary of the Commencement Date, which such date is January 8, 2031 (the "<u>Termination Date</u>"), but not thereafter, to subscribe for and purchase from Atlas Critical Minerals Corporation, a Republic of the Marshall Islands corporation (the "<u>Company</u>"), up to __________ shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>," and such shares of Common Stock underlying this Warrant, subject to adjustment hereunder, the "<u>Warrant Shares</u>") of the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

<u>Section 1</u>. <u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement, dated January 8, 2026 (as may be amended from time to time, the "<u>Underwriting Agreement</u>"), by and between the Company and A.G.P./Alliance Global Partners (the "<u>Representative</u>"), as representative of the several underwriters named therein.

<sup>1</sup> A number of Warrant Shares equal to 6.0% of the Company's shares of Common Stock sold in the Offering.

<u>Section 2</u>. <u>Exercise</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Exercise of Warrant</u>. Subject to the terms and conditions hereof, exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as <u>Exhibit A</u> (the "<u>Notice of Exercise</u>"). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is applicable and specified in the attached Notice of Exercise. The Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person executing such Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. **The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Exercise Price</u>. The exercise price per Warrant Share under this Warrant shall be **$9.20<sup>2</sup>**, subject to adjustment hereunder (the "<u>Exercise Price</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a "cashless exercise" in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

---

| | |
|:---|:---|
| (A) = | as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of "regular trading hours" (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of "regular trading hours" on such Trading Day; |

---

<sup>2</sup> Insert price equal to 115% of the underwritten offering price per share of the Company's common stock.

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

"<u>Bid Price</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported on the OTCQB Venture Market ("<u>OTCQB</u>") or the OTCQX Best Market ("<u>OTCQX</u>"), as applicable, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices for the Common Stock are then reported on the OTCID™ Basic Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

"<u>VWAP</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for the ten (10) Trading Days on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported on OTCQB or OTCQX, as applicable, the volume weighted average price of the Common Stock for the ten (10) Trading Days on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices for the Common Stock are then reported on the (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Mechanics of Exercise</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the "<u>Warrant Share Delivery Date</u>"). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the tenth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, "<u>Standard Settlement Period</u>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise, or gross negligence or willful misconduct of the Transfer Agent), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a "<u>Buy-In</u>"), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form, attached hereto as <u>Exhibit B</u>, duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vii. <u>Closing of Books</u>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Holder's Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates (such Persons, "<u>Attribution Parties</u>")), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on a number of outstanding shares of Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that was provided by the Company. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The "<u>Beneficial Ownership Limitation</u>" shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder's Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.

<u>Section 3</u>. <u>Certain Adjustments</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant or pursuant to any other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of the Common Stock any shares of share capital of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase shares, warrants, securities or other property pro rata to all of the record holders of any class of Common Stock (the "<u>Purchase Rights</u>"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all of the holders of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction but excluding any cash distribution) (a "<u>Distribution</u>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Notice to Holder</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock other than a share split, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of share capital of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby shares of Common Stock are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 4 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Company's subsidiaries, the Company shall file such notice with the Commission pursuant to a report of foreign private issuer on Form 6-K promptly. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Voluntary Adjustment by Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

<u>Section 4</u>. <u>Transfer of Warrant</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Transferability</u>. Pursuant to FINRA Rule 5110(e)(1)(A), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities for a period of 180 days beginning on the Commencement Date, or commencement of sales of the offering pursuant to which this Warrant is being issued, except as provided in FINRA Rule 5110(e)(2)(A). In addition, subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "<u>Warrant Register</u>"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

<u>Section 5</u>. <u>Registration of Warrant</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) "<u>Piggy-Back" Registration</u>. Unless all of the Common Stock underlying this Warrant (collectively, the "<u>Registrable Securities</u>") are included in an effective registration statement with a current prospectus, the Holder shall have the right, commencing on the date that this Warrant becomes exercisable to include the remaining Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145 promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock of Registrable Securities which may be included in the registration statement because, in such underwriter(s)' judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit; and further provided that no such piggy-back rights shall exist for so long as the Registrable Securities (which term shall include those paid as consideration pursuant to the cashless exercise provisions of this Warrant) may be sold pursuant to Rule 144 of the Securities Act without restriction. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not less than fifteen (15) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the "piggy-back" rights provided for herein by giving written notice, within seven (7) days of the receipt of the Company's notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 5(a). The demand for any "piggy-back registration" under this section expires on the seventh anniversary of the Commencement Date in accordance with FINRA Rule 5110(g)(8)(D). The Company covenants and agrees to give written notice of its receipt of any notice by any Holder(s) under this section to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Demand Registration Rights</u>. Solely in the event there is not then a current registration statement concerning the resale of the Registrable Securities, at any time commencing on the date that this Warrant becomes exercisable until the Termination Date, the Holder is entitled to one "demand" registration right at the Company's sole expense and an additional "demand" registration right at the Holder's expense. Upon receipt of a demand registration request from the Holder, the Company shall prepare and file with the Commission a required registration statement (the "<u>Required Registration Statement</u>") concerning the resale of all of the Registrable Securities. The Required Registration Statement shall be on Form F-3 if available for such a registration and if unavailable, the Company shall register the resale of the Registrable Securities on Form F-1 or another appropriate form reasonably acceptable to the Holder and undertake to register the resale of the Registrable Securities on Form F-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of all Registration Statements then in effect until such time as a Registration Statement on Form F-3 covering the resale of all of the Registrable Securities has been declared effective by the Commission and the prospectus contained therein is available for use. Within ten (10) days after receiving written notice from the Holder, the Company shall give notice to the other Holders of the Warrants advising that the Company is proceeding with such registration statement and offering to include therein Warrants of such other Holders. The Company shall not be obligated to any such other Holder unless such other Holder shall accept such offer by notice in writing to the Company within five (5) days thereafter. The Company shall use its best efforts to have such Required Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this Warrant, declared effective by the Commission as soon as practicable. The Company shall pay the costs and expenses thereof, for one time only, which costs and expenses shall include "Blue Sky" fees for counsel for the Representative and "Blue Sky" filing fees to qualify the Warrants in those jurisdictions requested by the Holder. The demand for registration may be made at any time beginning on the Initial Exercise Date and expiring on the fifth anniversary of the Commencement Date in accordance with FINRA Rule 5110(g)(8)(C). The Company covenants and agrees to give written notice of its receipt of any notice by any Holder(s) under this section to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Expenses of Registration</u>. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5(b) hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Indemnification</u>. The Company shall indemnify, to the fullest extent permitted by applicable laws, the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys' fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriter contained in Section 5 of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Exercise of Warrants</u>. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Documents to be Delivered by Holder(s)</u>. Each of the Holder(s) participating in any of the registration statement filed by the Company shall furnish to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Damages</u>. Should the registration or the effectiveness thereof required by Section 5 hereof be delayed by the Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

<u>Section 6</u>. <u>Miscellaneous</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>No Rights as Shareholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a "cashless exercise" as permitted in Section 2(c), and to receive the cash payments contemplated pursuant to Section 2(d)(i) and Section 2(d)(iv), in no event will the Company be required to net cash settle an exercise of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment (it being understood that this Warrant shall not in any case prevent the Company from effecting any such amendment, reorganization, transfer, consolidation, merger, dissolution, issuance or sale). Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action, which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h) <u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any shares of Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

[*Signature page follows.*]

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

---

| |
|:---|
| **ATLAS CRITICAL MINERALS CORPORATION** |
| By: |
| Name: |
| Title: |

---

[SIGNATURE PAGE TO COMMON STOCK PURCHASE WARRANT OF

ATLAS CRITICAL MINERALS CORPORATION]

**EXHIBIT A**

**NOTICE OF EXERCISE**

---

| | |
|:---|:---|
| TO: | **ATLAS CRITICAL MINERALS CORPORATION** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The undersigned hereby elects to purchase<u> </u> Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

[SIGNATURE OF HOLDER]

Name of Investing Entity: ____________________________________________________________________________

 

*Signature of Authorized Signatory of Investing Entity*: ______________________________________________________

Name of Authorized Signatory: ________________________________________________________________________

Title of Authorized Signatory: _________________________________________________________________________

Date: ____________________________________________________________________________________________

**EXHIBIT B**

**ASSIGNMENT FORM**

*(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)*

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

---

| | |
|:---|:---|
| Name: | |
|  | (Please Print) |
| Address: |  |
|  | (Please Print) |
| Phone Number: | |
| Email Address: | |
| Dated: _______ , ________ |  |
| Holder's Signature: _________________________ |  |
| Holder's Address: ___________________________ |  |

---

**<u>EXHIBIT B</u>**

**Lock-Up Agreement**

[●], 2026

A.G.P./Alliance Global Partners

Banco Bradesco BBI S.A.

As Representatives of the several Underwriters

c/o A.G.P./Alliance Global Partners

590 Madison Avenue, 28th Floor

New York, New York 10022

Banco Bradesco BBI S.A.

Avenida Juscelino Kubitschek, 1,309, 10<sup>th</sup> Floor

04543-011 São Paulo, São Paulo, Brazil

**Re: <u>Atlas Critical Minerals Corporation</u>**

Ladies and Gentlemen:

The undersigned understands that A.G.P./Alliance Global Partners ("***A.G.P.***") and Banco Bradesco BBI S.A. (hereinafter referred to as "you" (including its correlatives) or the "***Representatives***"), as the representatives of the Underwriters (the "***Underwriters***") propose to enter into an Underwriting Agreement (the "***Underwriting Agreement***") with the Company (as defined below) providing for the offer and sale (the "***Offering***") of shares (the "***Shares***") of common stock, par value $0.001 per share (the "***Common Stock***"), of Atlas Critical Minerals Corporation, a Republic of the Marshall Islands corporation (the "***Company***").

In consideration of the execution of the Underwriting Agreement by the Representatives, and for other good and valuable consideration, the undersigned hereby irrevocably agrees that, without the prior written consent of A.G.P., the undersigned will not, directly or indirectly, (a) offer for sale, sell, pledge, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock (including, without limitation, shares of Common Stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and shares of Common Stock that may be issued upon exercise of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock; (b) enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of Common Stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise; (c) except as provided for below, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock or any other securities of the Company; or (d) publicly disclose the intention to do any of the foregoing for a period commencing on the date hereof and ending one-hundred eighty (180) days after the date of the closing date of the Offering (such 180-day period, the "***Lock-Up Period***").

The foregoing paragraph shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in the open market after the completion of the Offering, *provided, that* no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), shall be required or shall be voluntarily made in connection with such transactions; (b) bona fide gifts of shares of Common Stock or any security convertible into shares of Common Stock, in each case that are made exclusively between and among the undersigned or members of the undersigned's family, or affiliates of the undersigned, including its partners (if a partnership) or members (if a limited liability company); (c) any transfer of shares of Common Stock or any security convertible into Common Stock by will or intestate succession upon the death of the undersigned; (d) transfer of shares of Common Stock or any security convertible into Common Stock to an immediate family member (for purposes of this Lock-Up Letter Agreement, "***immediate family***" shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) or any trust, limited partnership, limited liability company or other entity for the direct or indirect benefit of the undersigned or any immediate family member of the undersigned; *provided, that*, in the case of clauses (b), (c) and (d) above, it shall be a condition to any such transfer that (i) the transferee/donee agrees to be bound by the terms of this Lock-Up Letter Agreement (including, without limitation, the restrictions set forth in the preceding sentence) to the same extent as if the transferee/donee were a party hereto; and (ii) each party (donor, donee, transferor or transferee) shall not be required by law (including without limitation the disclosure requirements of the Securities Act of 1933, as amended (the "***Securities Act***"), and the Exchange Act) to make, and shall agree to not voluntarily make, any filing or public announcement of the transfer or disposition prior to the expiration of the 180-day period referred to above; (e) the transfer of shares to the Company (or withholding of shares of Common Stok by the Company) as payment for the exercise price of any options, or to satisfy withholding obligations for any equity award granted pursuant to the terms of the Company's stock option/incentive plans, such as upon exercise, vesting, lapse of substantial risk of forfeiture, or other similar taxable event, in each case on a "cashless" or "net exercise" basis (which, for the avoidance of doubt shall not include "cashless" exercise programs involving a broker or other third party), *provided* that as a condition of any transfer pursuant to this clause (e), that if the undersigned is required to file a report under Section 16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock during the Lock-Up Period, the undersigned shall include a statement in such report, and if applicable an appropriate disposition transaction code, to the effect that such transfer is being made as a share delivery or forfeiture in connection with a net value exercise, or as a forfeiture or sale of shares solely to cover required tax withholding, as the case may be; (f) transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock pursuant to (i) a bona fide third party tender offer made to all holders of the Common Stock, (ii) merger, (iii) consolidation or (iv) other similar transaction involving a change of control (as defined below) of the Company, including voting in favor of any such transaction or taking any other action in connection with such transaction, *provided, that* in the event that such merger, tender offer or other transaction is not completed, the Common Stock and any security convertible into or exercisable or exchangeable for Common Stock shall remain subject to the restrictions set forth herein; (g) the vesting of equity awards, the exercise of warrants or the exercise of stock options granted pursuant to the Company's stock option/incentive plans or otherwise outstanding on the date hereof; *provided*, that the restrictions shall apply to shares of Common Stock issued upon such vesting, exercise or conversion; (h) the establishment of any, or the continued use of any existing, contract, instruction or plan that satisfies all of the requirements of Rule 10b5-1 (a "***Rule 10b5-1 Plan***") under the Exchange Act, which Rule 10b5-1 Plan is in effect as of the date of the Underwriting Agreement (and any related filings in connection with such sale or disposition that are required under the Exchange Act; *provided* that any such filings shall indicate by footnote disclosure or otherwise (1) that such sale or disposition was made in connection with a Rule 10b5-1 Plan and (2) the date such Rule 10b5-1 Plan was entered into); *provided further*, *however*, that no sales of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock, shall be made pursuant to a Rule 10b5-1 Plan that is established during the Lock-Up Period prior to the expiration of the Lock-Up Period; *provided further*, that the Company does not otherwise voluntarily effect any such public filing or report regarding such Rule 10b5-1 Plan (for the avoidance of doubt, the Company shall not be prohibited from reporting the establishment of a Rule 10b5-1 Plan in accordance with the applicable requirements of the Commission); and (i) any demands or requests for, exercise any right with respect to, or take any action in preparation of, the registration by the Company under the Securities Act of the undersigned's shares of Common Stock, provided that no transfer of the undersigned's shares of Common Stock registered pursuant to the exercise of any such right and no registration statement shall be filed under the Securities Act with respect to any of the undersigned's shares of Common Stock during the Lock-Up Period. For purposes of clause (f) above, "**change of control**" shall mean the consummation of any bona fide third party tender offer, merger, purchase, consolidation or other similar transaction the result of which is that any "**person**" (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total voting power of the voting stock of the Company.

It is understood that, if the Company notifies the Representatives that it does not intend to proceed with the Offering, if the Underwriting Agreement does not become effective, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated with the Representatives prior to payment for and delivery of the shares of Common Stock to be sold in the Offering, the undersigned will be released from its obligations under this Lock-Up Letter Agreement.

The undersigned understands that the Company and the Representatives will proceed with the Offering in reliance on this Lock-Up Letter Agreement.

Whether or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Representatives.

This Lock-Up Letter Agreement shall automatically terminate upon (a) the termination of the Underwriting Agreement prior to the issuance and delivery of the Shares, (b) the date that either the Company or A.G.P. provides written notice to the other that it has determined not to proceed with the proposed Offering and, with respect to the Company, is terminating this Lock-Up Letter Agreement on behalf of all of the Company's holders of securities subject to a Lock-Up Letter Agreement, provided that the Company and the Representatives shall not have executed the Underwriting Agreement on or prior to such date. Notwithstanding anything herein to the contrary, this Lock-Up Letter Agreement shall lapse and become null and void if the closing of the Offering shall not have occurred on or before January 31, 2026.

This Lock-Up Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. Delivery of a signed copy of this Lock-Up Letter Agreement by facsimile or e-mail/.pdf transmission shall be effective as the delivery of the original hereof.

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Letter Agreement and that, upon request, the undersigned will execute any additional documents necessary in connection with the enforcement hereof. Any obligations of the undersigned shall be binding upon the heirs, personal representative, successors and assigns of the undersigned.

[Signature page follows]

---

| |
|:---|
| Very truly yours, |
| (Name) |
| (Signature) |
| (Name of Signatory, in the case of entities – Please Print) |
| (Title of Signatory, in the case of entities – Please Print) |
| Address: ________________________________________ |

---

**<u>EXHIBIT C</u>**

**Company Introduced Accounts**

Joe Stroffolino

Ron Zelazo Rev. Trust

Stephen Petersen

World Total Return Fund

Robby Routt

Lincoln Park Capital

Gordon Holmes

Warberg Funds

Gary Routt

Atlas Lithium Corp.

Ted M. Routt

Warberg Special Situations Fund LP

Warberg Wf Xiii LP

World Total Return Fund LLLP

## Exhibit 1.2

**Exhibit 1.2**

![](ex1-2_001.jpg)

**CONFIDENTIAL**

January 12, 2026

Atlas Critical Minerals Corporation

Rua Antônio de Albuquerque, 156, Suite 1720

Belo Horizonte, Minas Gerais, Brazil, 30112-010

The purpose of this financial advisory agreement (this "**Agreement**") is to confirm the engagement of A.G.P./Alliance Global Partners ("**A.G.P.**") by Atlas Critical Minerals Corporation, a Republic of the Marshall Islands corporation (the "**Company**") for financial advisory services provided during the uplisting (the "**Uplisting**") of its common stock from trading on the OTCQB operated by the OTC Markets Group, Inc. to the Nasdaq Stock Market LLC and related matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Services</u>. A.G.P. has provided advice to, and consulted with, the Company regarding strategic advice and market information with respect to the Company's Uplisting (collectively, the "**Financial Services**").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Compensation</u>. As compensation for the Financial Services, the Company has agreed to pay A.G.P. a cash fee (the "**Cash Fee**") equal to $135,000 upon execution of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Reserved.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Reserved</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Indemnity</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. In connection with the Company's engagement of A.G.P. pursuant to the terms herewith, the Company hereby agrees to indemnify and hold harmless A.G.P. and its affiliates, and the respective controlling persons, directors, officers, agents and employees of any of the foregoing (collectively the "**Indemnified Persons**"), from and against any and all claims, actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses actually incurred by any of them (including the reasonable out-of-pocket fees and expenses of counsel), as incurred, (collectively a "**Claim**"), that are (A) related to or arise out of (i) any actions taken or omitted to be taken (including any untrue statements made or any statements omitted to be made) by the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in connection with the Company's engagement of A.G.P., or (B) otherwise relate to or arise out of A.G.P.'s engagement, and the Company shall reimburse any Indemnified person for all expenses (including the reasonable out-of-pocket fees and expenses of counsel) as incurred by such Indemnified Person in connection with investigating, preparing or defending any such claim, action, suit or proceeding, whether or not in connection with pending or threatened litigation in which any Indemnified Person is a party; provided, however, that the Company shall not be liable in any such case to the extent that any such Claim arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in connection with the Company's engagement of A.G.P. in reliance upon and in conformity with written information furnished to the Company by A.G.P. (or any Indemnified Party) or its agent expressly for use. The Company will not be responsible for any Claim that is finally judicially determined to have resulted from the gross negligence, violation of law, or willful misconduct of any Indemnified Person. The Company further agrees that no Indemnified Person shall have any liability to the Company for or in connection with the Company's engagement of A.G.P. except for any Claim incurred by the Company as a result of such Indemnified Person's gross negligence, violation of law, or willful misconduct.

**590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC**<sub>1</sub>

![](ex1-2_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Company further agrees that it will not, without the prior written consent of A.G.P (which shall not be unreasonably withheld, conditioned or delayed), settle, compromise or consent to the entry of any judgment in any pending or threatened Claim in respect of which indemnification may be sought hereunder (whether or not any indemnified Person is an actual or potential party to such Claim), unless such settlement, compromise or consent includes an unconditional, irrevocable release of each Indemnified Person from any and all liability arising out of such Claim.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion or institution of any Claim with respect to which indemnification is being sought hereunder, such Indemnified Person shall notify the Company in writing of such complaint or of such assertion or institution but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder, except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company so elects or is requested by such Indemnified Person, the Company will assume the defense of such Claim, including the employment of counsel reasonably satisfactory to such Indemnified Person and the payment of the reasonable out-of-pocket fees and expenses of such counsel. In the event, however, that legal counsel to such Indemnified Person reasonably determines that having common counsel would present such counsel with a conflict of interest or if the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses available to it or other Indemnified Persons different from or in addition to those available to the Company, then such Indemnified Person may employ its own separate counsel to represent or defend him, her or it in any such Claim and the Company shall pay the reasonable out-of-pocket fees and expenses of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified Person shall have the right, but not the obligation, to defend, contest, compromise, settle, assert crossclaims, or counterclaims or otherwise protect against the same, and shall be fully indemnified by the Company therefor, including without limitation, for the reasonable out-of-pocket fees and expenses of its counsel and all amounts paid as a result of such Claim or the compromise or settlement thereof. In addition, with respect to any Claim in which the Company assumes the defense, the Indemnified Person shall have the right to participate in such Claim and to retain his, her or its own counsel therefor at his, her or its own expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held by a court to be unavailable for any reason then (whether or not A.G.P. is the Indemnified Person), the Company and A.G.P. shall contribute to the Claim for which such indemnity is held unavailable in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and A.G.P. on the other, in connection with A.G.P.'s engagement referred to above, subject to the limitation that in no event shall the amount of A.G.P.'s contribution to such Claim exceed the amount of fees actually received by A.G.P. from the Company pursuant to A.G.P.'s engagement. The Company hereby agrees that the relative benefits to the Company, on the one hand, and A.G.P. on the other, with respect to A.G.P.'s engagement shall be deemed to be in the same proportion as (a) any value paid or proposed to be paid or received by the Company or its stockholders as the case may be to (b) the fee paid or proposed to be paid to A.G.P. in connection with such engagement.

**590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC**<sub>2</sub>

![](ex1-2_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E. The Company's indemnity, reimbursement and contribution obligations under this Agreement (a) shall be in addition to, and shall in no way limit or otherwise adversely affect any rights that any Indemnified Person may have at law or at equity, and (b) shall be effective whether or not the Company is at fault in any way.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Limitation of Engagement to the Company</u>. The Company acknowledges that A.G.P. has been retained only by the Company, that A.G.P. is providing services hereunder as an independent contractor (and not in any fiduciary or agency capacity) and that the Company's engagement of A.G.P. is not deemed to be on behalf of, and is not intended to confer rights upon, any shareholder, owner or partner of the Company or any other person not a party hereto as against A.G.P. or any of its affiliates, or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as amended (the "**Securities Act**"), or Section 20 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**")), employees or agents. Unless otherwise expressly agreed in writing by A.G.P., no one other than the Company is authorized to rely upon this Agreement or any other statements or conduct of A.G.P., and no one other than the Company is intended to be a beneficiary of this Agreement. The Company acknowledges that any recommendation or advice, written or oral, given by A.G.P. to the Company in connection with A.G.P.'s engagement is intended solely for the benefit and use of the Company's management and directors, and any such recommendation or advice is not on behalf of, and shall not confer any rights or remedies upon, any other person or be used or relied upon for any other purpose. A.G.P. shall not have the authority to make any commitment binding on the Company. The Company agrees that A.G.P. will be entitled to rely on the representation, warranties, agreements and covenants of the Company contained in any purchase agreement and related transaction documents as if such representations, warranties, agreements and covenants were made directly to A.G.P. by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Limitation of A.G.P.'s Liability to the Company</u>. A.G.P. and the Company further agree that neither A.G.P. nor any of its affiliates or any of its or their respective officers, directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), employees or agents shall have any liability to the Company, its security holders or creditors, or any person asserting claims on behalf of or in the right of the Company (whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any losses, fees, damages, liabilities, costs, expenses or equitable relief arising out of or relating to this Agreement or the Financial Services rendered hereunder, except for losses, fees, damages, liabilities, costs or expenses that arise out of or are based on any action of or failure to act by A.G.P. and that have resulted solely from the gross negligence, violation of law, or willful misconduct of A.G.P.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Amendment</u>. No amendment to this Agreement shall be valid unless such amendment is in writing and is signed by authorized representatives of all the parties to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Waiver</u>. Any of the terms and conditions of this Agreement may be waived at any time and from time to time in writing by the party entitled to the benefit thereof, but a waiver in one instance shall not be deemed to constitute a waiver in any other instance. A failure to enforce any provision of this Agreement shall not operate as a waiver of this provision or of any other provision hereof.

**590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC**<sub>3</sub>

![](ex1-2_001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Severability</u>. In the event that any provision of this Agreement shall be held to be invalid, illegal, or unenforceable in any circumstances, the remaining provisions shall nevertheless remain in full force and effect and shall be construed as if the unenforceable portion or portions were deleted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Governing Law</u>. This Agreement shall be exclusively governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein, and without regard to the conflict of laws principles therein. Any disputes that arise under this Agreement, even after the termination of this Agreement, will be heard only in the state or federal courts located in the City of New York, State of New York. The parties hereto expressly agree to submit themselves exclusively to the jurisdiction of the foregoing courts in the City of New York, State of New York. The parties hereto expressly waive any rights they may have to contest the jurisdiction, venue or authority of any court sitting in the City and State of New York. In the event of the bringing of any action, or suit by a party hereto against the other party hereto, arising out of or relating to this Agreement, the party in whose favor the final judgment or award shall be entered shall be entitled to have and recover from the other party the costs and expenses incurred in connection therewith, including its reasonable attorneys' fees. **EACH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL ACTION, PROCEEDING, CAUSE OF ACTION, OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT, INCLUDING ANY EXHIBITS, SCHEDULES, AND APPENDICES ATTACHED TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Counterparts; Facsimile</u>. This agreement may be executed in any number of counterparts, each of which may be deemed an original and all of which together will constitute one and the same instrument. A pdf or facsimile signature of any party shall be considered to have the same binding legal effect as an original signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Entire Agreement</u>. This Agreement contains the entire agreement between the parties with respect to the Financial Services and supersedes any and all prior or contemporaneous written or oral agreements relating to any Financial Services. Neither party is relying on any agreement, representation, warranty, or other understanding not expressly stated herein with respect to the Financial Services.

In acknowledgment that the foregoing correctly sets forth the understanding reached by A.G.P. and the Company, please sign and return to us one copy of this engagement letter. This engagement letter may be executed in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

[Signature Page Follows]

**590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC**<sub>4</sub>

![](ex1-2_001.jpg)

---

| | |
|:---|:---|
| Yours truly, | Yours truly, |
| **A.G.P./ALLIANCE GLOBAL PARTNERS** | **A.G.P./ALLIANCE GLOBAL PARTNERS** |
| By: | */s/ Thomas J. Higgins* |
|  | Name: Thomas J. Higgins |
|  | Title: Managing Director |

---

---

| | |
|:---|:---|
| Accepted and agreed to as of the date first written above: | Accepted and agreed to as of the date first written above: |
| **ATLAS CRITICAL MINERALS CORPORATION** | **ATLAS CRITICAL MINERALS CORPORATION** |
| By: | */s/ Marc Fogassa* |
|  | Name: Marc Fogassa |
|  | Title: Chief Executive Officer |

---

**590 Madison Avenue, 36th Floor, New York, NY 10022, 212-624-2060 Member FINRA, SIPC**<sub>5</sub>

## Exhibit 4.1

**Exhibit 4.1**

**Representative's Warrant Agreement**

**THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE COMMENCEMENT DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) A.G.P./ALLIANCE GLOBAL PARTNERS, OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF A.G.P./ALLIANCE GLOBAL PARTNERS OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.**

**THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO JULY 7, 2026. VOID AFTER 5:00 P.M., EASTERN TIME, ON JULY 7, 2031.**

**COMMON STOCK PURCHASE WARRANT**

**ATLAS CRITICAL MINERALS CORPORATION**

Warrant Shares: 82,800 Original Issue Date: January 12, 2026<br> Initial Exercise Date: July 7, 2026

THIS COMMON STOCK PURCHASE WARRANT (the "<u>Warrant</u>") certifies that, for value received, **A.G.P./Alliance Global Partners** or its assigns (the "<u>Holder</u>") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time from and after the 180th day from the date of effectiveness (the "<u>Commencement Date</u>") of those certain registration statements on (i) Form F-1, as amended (File No. 333-290242) and (ii) Form F-1 (MEF) (File No. 333-292623 (together, the "<u>Registration Statement</u>"), filed by the Company (the "<u>Initial Exercise Date</u>"), in accordance with FINRA Rule 5110(e)(1), and through and including the five (5) year anniversary of the Commencement Date, which such date is January 8, 2031 (the "<u>Termination Date</u>"), but not thereafter, to subscribe for and purchase from Atlas Critical Minerals Corporation, a Republic of the Marshall Islands corporation (the "<u>Company</u>"), up to **EIGHTY-TWO THOUSAND EIGHT HUNDRED (82,800)** shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>," and such shares of Common Stock underlying this Warrant, subject to adjustment hereunder, the "<u>Warrant Shares</u>") of the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

<u>Section 1</u>. <u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement, dated January 8, 2026 (as may be amended from time to time, the "<u>Underwriting Agreement</u>"), by and among the Company and A.G.P./Alliance Global Partners and Banco Bradesco BBI S.A. (the "<u>Representatives</u>"), as representatives of the several underwriters named therein.

<u>Section 2</u>. <u>Exercise</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Exercise of Warrant</u>. Subject to the terms and conditions hereof, exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form attached hereto as <u>Exhibit A</u> (the "<u>Notice of Exercise</u>"). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier's check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is applicable and specified in the attached Notice of Exercise. The Company shall have no obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person executing such Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. **The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Exercise Price</u>. The exercise price per Warrant Share under this Warrant shall be **$9.20**, subject to adjustment hereunder (the "<u>Exercise Price</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Cashless Exercise</u>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for, the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a "cashless exercise" in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = as
 applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
 of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a)
 hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a)
 hereof on a Trading Day prior to the opening of "regular trading hours" (as defined in
 Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
 (ii) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
 or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
 is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
 hereof after the close of "regular trading hours" on such Trading Day;

(B) = the
 Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the
 number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
 exercise were by means of a cash exercise rather than a cashless exercise.

"<u>Bid Price</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported on the OTCQB Venture Market ("<u>OTCQB</u>") or the OTCQX Best Market ("<u>OTCQX</u>"), as applicable, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices for the Common Stock are then reported on the OTCID™ Basic Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases, the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

"<u>VWAP</u>" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for the ten (10) Trading Days on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported on OTCQB or OTCQX, as applicable, the volume weighted average price of the Common Stock for the ten (10) Trading Days on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices for the Common Stock are then reported on the (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of one share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Mechanics of Exercise</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder's or its designee's balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (ii) the number of days comprising the Standard Settlement Period, in each case after the delivery to the Company of the Notice of Exercise (such date, the "<u>Warrant Share Delivery Date</u>"). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, provided that payment of the aggregate Exercise Price (other than in the instance of a cashless exercise) is received by the Company by such date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the tenth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, "<u>Standard Settlement Period</u>" means the standard settlement period, expressed in a number of Trading Days, on the Company's primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by delivering written notice to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise, or gross negligence or willful misconduct of the Transfer Agent), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder's brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a "<u>Buy-In</u>"), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder's total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder's right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vi. <u>Charges, Taxes and Expenses</u>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form, attached hereto as <u>Exhibit B</u>, duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;vii. <u>Closing of Books</u>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Holder's Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder's Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder's Affiliates (such Persons, "<u>Attribution Parties</u>")), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder's determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on a number of outstanding shares of Common Stock that was provided by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that was provided by the Company. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The "<u>Beneficial Ownership Limitation</u>" shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder's Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.

<u>Section 3</u>. <u>Certain Adjustments</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Stock Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant or pursuant to any other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of the Common Stock any shares of share capital of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Warrant is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase shares, warrants, securities or other property pro rata to all of the record holders of any class of Common Stock (the "<u>Purchase Rights</u>"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all of the holders of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction but excluding any cash distribution) (a "<u>Distribution</u>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Notice to Holder</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock other than a share split, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of share capital of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby shares of Common Stock are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 4 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Company's subsidiaries, the Company shall file such notice with the Commission pursuant to a report of foreign private issuer on Form 6-K promptly. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Voluntary Adjustment by Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

<u>Section 4</u>. <u>Transfer of Warrant</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Transferability</u>. Pursuant to FINRA Rule 5110(e)(1)(A), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities for a period of 180 days beginning on the Commencement Date, or commencement of sales of the offering pursuant to which this Warrant is being issued, except as provided in FINRA Rule 5110(e)(2)(A). In addition, subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the "<u>Warrant Register</u>"), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

<u>Section 5</u>. <u>Registration of Warrant</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) "<u>Piggy-Back" Registration</u>. Unless all of the Common Stock underlying this Warrant (collectively, the "<u>Registrable Securities</u>") are included in an effective registration statement with a current prospectus, the Holder shall have the right, commencing on the date that this Warrant becomes exercisable to include the remaining Registrable Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145 promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock of Registrable Securities which may be included in the registration statement because, in such underwriter(s)' judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit; and further provided that no such piggy-back rights shall exist for so long as the Registrable Securities (which term shall include those paid as consideration pursuant to the cashless exercise provisions of this Warrant) may be sold pursuant to Rule 144 of the Securities Act without restriction. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not less than fifteen (15) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise the "piggy-back" rights provided for herein by giving written notice, within seven (7) days of the receipt of the Company's notice of its intention to file a registration statement. Except as otherwise provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 5(a). The demand for any "piggy-back registration" under this section expires on the seventh anniversary of the Commencement Date in accordance with FINRA Rule 5110(g)(8)(D). The Company covenants and agrees to give written notice of its receipt of any notice by any Holder(s) under this section to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Demand Registration Rights</u>. Solely in the event there is not then a current registration statement concerning the resale of the Registrable Securities, at any time commencing on the date that this Warrant becomes exercisable until the Termination Date, the Holder is entitled to one "demand" registration right at the Company's sole expense and an additional "demand" registration right at the Holder's expense. Upon receipt of a demand registration request from the Holder, the Company shall prepare and file with the Commission a required registration statement (the "<u>Required Registration Statement</u>") concerning the resale of all of the Registrable Securities. The Required Registration Statement shall be on Form F-3 if available for such a registration and if unavailable, the Company shall register the resale of the Registrable Securities on Form F-1 or another appropriate form reasonably acceptable to the Holder and undertake to register the resale of the Registrable Securities on Form F-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of all Registration Statements then in effect until such time as a Registration Statement on Form F-3 covering the resale of all of the Registrable Securities has been declared effective by the Commission and the prospectus contained therein is available for use. Within ten (10) days after receiving written notice from the Holder, the Company shall give notice to the other Holders of the Warrants advising that the Company is proceeding with such registration statement and offering to include therein Warrants of such other Holders. The Company shall not be obligated to any such other Holder unless such other Holder shall accept such offer by notice in writing to the Company within five (5) days thereafter. The Company shall use its best efforts to have such Required Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this Warrant, declared effective by the Commission as soon as practicable. The Company shall pay the costs and expenses thereof, for one time only, which costs and expenses shall include "Blue Sky" fees for counsel for the Representatives and "Blue Sky" filing fees to qualify the Warrants in those jurisdictions requested by the Holder. The demand for registration may be made at any time beginning on the Initial Exercise Date and expiring on the fifth anniversary of the Commencement Date in accordance with FINRA Rule 5110(g)(8)(C). The Company covenants and agrees to give written notice of its receipt of any notice by any Holder(s) under this section to all other registered Holders of the Warrants and/or the Registrable Securities within ten (10) days after the date of the receipt of any such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Expenses of Registration</u>. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 5(b) hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Indemnification</u>. The Company shall indemnify, to the fullest extent permitted by applicable laws, the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys' fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriter contained in Section 5 of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Exercise of Warrants</u>. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Documents to be Delivered by Holder(s)</u>. Each of the Holder(s) participating in any of the registration statement filed by the Company shall furnish to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Damages</u>. Should the registration or the effectiveness thereof required by Section 5 hereof be delayed by the Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security.

<u>Section 6</u>. <u>Miscellaneous</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) <u>No Rights as Shareholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a "cashless exercise" as permitted in Section 2(c), and to receive the cash payments contemplated pursuant to Section 2(d)(i) and Section 2(d)(iv), in no event will the Company be required to net cash settle an exercise of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment (it being understood that this Warrant shall not in any case prevent the Company from effecting any such amendment, reorganization, transfer, consolidation, merger, dissolution, issuance or sale). Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action, which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder's rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys' fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. h) <u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Underwriting Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;h) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any shares of Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;j) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;k) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;l) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;m) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;n) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

[*Signature page follows.*]

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

---

| |
|:---|
| **Atlas Critical Minerals CorpORATION** |
| By: |
| Name: |
| Title: |

---

[SIGNATURE PAGE TO COMMON STOCK PURCHASE WARRANT OF ATLAS CRITICAL MINERALS CORPORATION]

**EXHIBIT A**

**NOTICE OF EXERCISE**

---

| | |
|:---|:---|
| TO: | **Atlas Critical Minerals CorpORATION** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

[SIGNATURE OF HOLDER]

Name of Investing Entity: _______________________________________________________

*Signature of Authorized Signatory of Investing Entity*: __________________________________

Name of Authorized Signatory: __________________________________________________

Title of Authorized Signatory: ____________________________________________________

Date: _________________________________________________________________________

**EXHIBIT B**

**ASSIGNMENT FORM**

*(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)*

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

---

| | |
|:---|:---|
| Name: | |
|  | (Please Print) |
| Address: | |
|  | (Please Print) |
| Phone Number: | |
| Email Address: | |
| Dated: _______________ __, ______ |  |
| Holder's Signature: ___________________ |  |
| Holder's Address: ____________________ |  |

---

## Exhibit 99.1

**Exhibit 99.1**

**Atlas Critical Minerals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Over-Allotment Option**

**BELO HORIZONTE, Brazil, January 12, 2026** - Atlas Critical Minerals Corporation (NASDAQ: ATCX) ("Atlas Critical Minerals" or "the Company"), a company focused on critical minerals for advanced technology uses, energy transition, and defense applications, announced today the closing of its upsized firm commitment underwritten public offering of 1,380,000 shares of its common stock, including 180,000 shares of its common stock pursuant to the full exercise of the underwriters' over-allotment option, at a public price of $8.00 per share. The gross proceeds from the offering were approximately $11.0 million before offering expenses and underwriting discounts and commissions. On January 8, 2026, the Company received approval to list its common stock on the Nasdaq Capital Market stock exchange ("Nasdaq"). Trading on Nasdaq commenced on January 9, 2026 under the ticker symbol "ATCX."

Atlas Critical Minerals intends to use the net proceeds from this offering to advance exploration and development activities across its critical minerals project portfolio in Brazil, with any surplus intended to be used for general working capital, cash reserves, or other corporate purposes at the discretion of management.

Marc Fogassa, Chairman and CEO of Atlas Critical Minerals, stated: "The Nasdaq uplisting represents a significant milestone for the Company. We are encouraged by the level of investor interest resulting in the upsizing of the offering, demonstrating strong support for the Company's path forward. This capital raise strengthens our financial position to advance our diversified critical minerals portfolio. Achieving a Nasdaq listing, a premier stock exchange, will also allow our common stock to achieve increased liquidity and accessibility by a broader investor base."

A.G.P./Alliance Global Partners and Bradesco BBI acted as book-running managers for the offering.

A registration statement on Form F-1 relating to the securities (File No. 333-290242) was previously filed with the Securities and Exchange Commission ("SEC") and was declared effective on January 8, 2026, and an additional registration statement on Form F-1 (File No. 333-292623) was filed pursuant to Rule 462(b) on January 8, 2026 and became automatically effective upon filing. This offering was made only by means of a prospectus forming part of the effective registration statement. Copies of the prospectus may be obtained on the SEC's website at http://www.sec.gov. Electronic copies of the prospectus may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com or from Bradesco Securities Inc., 450 Park Avenue 32nd floor, New York, NY 10022.

 

*This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.*

**About Atlas Critical Minerals Corporation** 

Atlas Critical Minerals Corporation (NASDAQ: ATCX) controls a large portfolio of critical mineral rights in Brazil, encompassing over 218,000 hectares, and including projects in rare earths, titanium, graphite, and uranium – minerals essential for advanced technology uses, energy transition, and defense applications. Additionally, the Company's first iron ore project began operations in November 2025. More information is available in the Company's filings with the U.S. Securities and Exchange Commission.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements include without limitation, statements regarding the use of net proceeds from the offering. Forward-looking statements are based upon the current plans, estimates and projections of Atlas Critical Minerals and its subsidiaries and are subject to inherent risks and uncertainties which could cause actual results to differ from the forward-looking statements, including, without limitation, risks and uncertainties related to market conditions, the Company's ability to continue as a going concern and its history of losses, the Company's ability to obtain additional financing, the Company's ability to study and properly explore the various mineral rights that it owns, the Company's ability to obtain the necessary permitting for mining and processing material obtained in mining, the accuracy of the Company's estimates regarding expenses, future revenues and capital requirements, the implementation of the Company's business model and strategic plans for its business, the Company's ability to retain key management personnel, regulatory developments and the Company's compliance with applicable laws, as well as those risks described under "Risk Factors" in the prospectus related to the offering. Therefore, you should not place undue reliance on these forward-looking statements.

Risks related to the Company and its subsidiaries are also discussed in the section entitled "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission (the "SEC") on February 28, 2025. Please also refer to the Company's other filings with the SEC, all of which are available at www.sec.gov. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update or revise any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

**Investor Relations**<br> Brian W. Bernier<br> Vice President, Investor Relations<br> +1 (833) 661-7900<br> <u>brian.bernier@atlas-cm.com</u>